Cover page 
Official Title: 
PROTOCOL ID-078A301 - Multi-center, double-b lind, randomized, placebo-controlled, 
parallel-group, polysomnography study to  assess the efficacy and safety of  
ACT-541468 in adult and elderly s ubjects with insomnia disorder 
Study Registry ID: [REMOVED] 
Date of document: 
[ADDRESS_422902] -541468 in adult and 
elderly subjects with insomnia disorder  
Study Phase:  [ADDRESS_422903]  Number:  2017 -004642 -20 
Status and version:  Final  Version  4 
Date:  30 July 2018  
Document type : Amended g lobal p rotocol  
Idorsia  document number 
(Doc No.): D-18.[ADDRESS_422904] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 2/[ADDRESS_422905] DETAILS 
Sponsor  Idorsia Pharmaceuticals Ltd  
Hegenheimermattweg 91  
CH-4123 Allschwil 
Switzerland  
 [PHONE_744] [ADDRESS_422906] Research Organizations (CROs). A 
list of site -specific contact [CONTACT_42886].  
 
  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 4/[ADDRESS_422907] 2017 -004642 -20 
Doc No D- 18.160 
 
INVESTIGATOR SIGNATURE [CONTACT_180549] / number 
ACT -[ADDRESS_422908] -541468 in adult and 
elderly subjects with insomnia disorder 
I agree to the terms and conditions relating to this study as defined in this protocol, the 
Case Report Form, and any other protocol -related documents. I fully understand that any 
changes instituted by [CONTACT_093](s) without previous agreement with the sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study subjects (other tha n those procedures necessary for the well -being of 
the subjects).  
I agree to conduct this study in accordance with the Declaration of Helsinki principles, ICH  
GCP guidelines, and applicable regulations and laws. I confirm herewith that the sponsor is allow ed to enter and utilize my professional contact [CONTACT_341786]. 
I am participating in the following sub -study (only for sites in [LOCATION_013] and the [LOCATION_003]) : 
PAtient Preferences StUdy in InSomnia (PAUSe)  
 
Principal 
Investigator  [INVESTIGATOR_223106] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 5/[ADDRESS_422909] OF ABBREVIATION S AND ACRONYMS  ..........................................................12  
NON- SUBSTANTIAL GLOBAL AMENDMENT 3  .......................................................16  
PROTOCOL SYNOPSIS ID-078A301 .............................................................................18  
PROTOCOL  ......................................................................................................................32  
1 BACKGROUND  .........................................................................................................32  
1.1 Insomnia disorder .........................................................................................32  
1.1.1  Definition  ..........................................................................................32  
1.1.2  Epi[INVESTIGATOR_623] ....................................................................................32  
1.1.3  Treatment  ..........................................................................................33  
1.1.4  Unmet medical need  .........................................................................34  
1.2 Study treatment: ACT -[ADDRESS_422910] -541468 properties ....................................................................35  
[IP_ADDRESS]  Nonclinical data  .......................................................................35  
[IP_ADDRESS]  Clinical studies  ........................................................................[ADDRESS_422911] -541468 .....................................................................................40  
1.4.2  Safety and risk -minimization measures taken in the present 
study ..................................................................................................41  
2 STUDY OBJECTIVES  ...............................................................................................41  
2.1 Primary objective  ..........................................................................................41  
2.2 Secondary objectives ....................................................................................42  
2.3 Safety objectives  ...........................................................................................42  
3 OVERALL STUDY DESIGN AND PLAN  ...............................................................42  
3.1 Study design .................................................................................................42  
3.1.1  Study periods ....................................................................................42  
[IP_ADDRESS]  Screening phase  .......................................................................42  
[IP_ADDRESS]  Treatment phase  ......................................................................43  
[IP_ADDRESS]  Safety follow -up phase ............................................................[ADDRESS_422912] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 6/[ADDRESS_422913] 2017 -004642 -20 
Doc No D- 18.160 
 
3.1.2  Study duration ...................................................................................44  
3.1.3  Sub- study – Patient Preferences  .......................................................[ADDRESS_422914] population description .....................................................................48  
4.2 Rationale for the selection of the study population ......................................48  
4.3 Inclusion criteria  ...........................................................................................48  
4.4 Exclusion criteria  ..........................................................................................50  
4.5 Criteria for women of childbearing potential ...............................................52  
4.5.1  Definition of childbearing potential ..................................................52  
4.5.2  Acceptable methods of contraception ...............................................53  
5 TREATMENTS  ..........................................................................................................53  
5.1 Study treatment  .............................................................................................53  
5.1.1  Investigational treatment and matching placeb o: Description 
and rationale ......................................................................................53  
5.1.2  Study treatment administration  .........................................................54  
[IP_ADDRESS]  Study treatment administration at site visits and at home  .......54  
[IP_ADDRESS]  Missed doses ............................................................................54  
5.1.3  Treatment assignment  .......................................................................54  
5.1.4  Blinding ............................................................................................55  
[IP_ADDRESS]  Run-in and run-out periods ......................................................55  
[IP_ADDRESS]  Double- blind treatment period  ................................................55  
5.1.5  Unblinding ........................................................................................56  
[IP_ADDRESS]  Unblinding for final analyses ..................................................56  
[IP_ADDRESS]  Unblinding for IDMC review ..................................................56  
[IP_ADDRESS]  Unblinding for suspected unexpected serious adverse 
reactions  ...................................................................................56  
[IP_ADDRESS]  Emergen cy procedure for unblinding ......................................56  
5.1.6  Study treatment supply .....................................................................56  
[IP_ADDRESS]  Study treatment packaging and labeling  .................................57  
[IP_ADDRESS]  Study treatment distribution and storage .................................57  
[IP_ADDRESS]  Study treatment dispensing .....................................................57  
[IP_ADDRESS]  Study treatment return and destruction ...................................[ADDRESS_422915] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 7/[ADDRESS_422916] 2017 -004642 -20 
Doc No D- 18.160 
 
[IP_ADDRESS]  Study treatment accountability  ................................................57  
[IP_ADDRESS]  Study treatment compliance  ....................................................[ADDRESS_422917] udy treatment  ..................................59  
5.1.10  Study- specific criteria for interruption / premature 
discontinuation of study treatment ....................................................60  
5.2 Previous and concomitant therapy ................................................................60  
5.2.1  Definitions  ........................................................................................60  
5.2.2  Reporting of previous/concomitant therapy in the eCRF .................60  
5.2.3  Allowed concomitant therapy ...........................................................60  
5.2.4  Forbidden concomitant therapy ........................................................61  
5.2.5  Forbidden concomitant diet and activities ........................................61  
6 STUDY ENDPOINTS  ................................................................................................62  
6.1 Primary efficacy endpoints  ...........................................................................62  
6.2 Secondary endpoints .....................................................................................62  
6.3 Other efficacy endpoints ...............................................................................63  
6.4 Exploratory endpoints ...................................................................................63  
6.5 Safety endpoints  ...........................................................................................64  
6.6 Pharmacokinetic endpoints ...........................................................................65  
6.7 Patient preferences exploratory endpoints ....................................................65  
7 VISIT SCHEDULE AND STUDY ASSESSMENTS  ................................................65  
7.1 Study visits  ...................................................................................................65  
7.1.1  Screening  ..........................................................................................66  
7.1.2  Unscheduled visits ............................................................................66  
7.2 Study assessments  .........................................................................................69  
7.2.1  Demographics ...................................................................................71  
7.2.2  Efficacy assessments  .........................................................................71  
[IP_ADDRESS]  Polysomnography ....................................................................71  
[IP_ADDRESS]  Sleep diary  ...............................................................................73  
[IP_ADDRESS]  Insomnia Severity Index© ........................................................73  
[IP_ADDRESS]  Patient Global Assessment of Disease Severity  ......................74  
[IP_ADDRESS]  Patient Global Impression of Change (daytime 
symptoms)  ...............................................................................74  
[IP_ADDRESS]  Patient Global Impression of Change (night- time 
symptoms)  ...............................................................................74  
[IP_ADDRESS]  Patient Global Impres sion of Severity .....................................75  
[IP_ADDRESS]  Insomnia Daytime Symptoms and Impacts Questionnaire  .....[ADDRESS_422918] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 8/[ADDRESS_422919] 2017 -004642 -20 
Doc No D- 18.160 
 
[IP_ADDRESS]  Weight and height ...................................................................75  
[IP_ADDRESS]  Physical examination  ...............................................................75  
[IP_ADDRESS]  Vital signs  ................................................................................76  
[IP_ADDRESS]  Coding sub- test© ......................................................................76  
[IP_ADDRESS]  Sheehan Disability Scale© .......................................................76  
[IP_ADDRESS]  Columbia Suicide Severity Rating Scale©...............................76  
[IP_ADDRESS]  Benzodiazepi[INVESTIGATOR_42831] ............77  
[IP_ADDRESS]  Mini International Neuropsychiatric Interview© .....................77  
[IP_ADDRESS]  Mini Mental State Examination© ............................................77  
[IP_ADDRESS]  Neurological examinations  ......................................................78  
[IP_ADDRESS]  Epworth Sleepi[INVESTIGATOR_7110]© ......................................................78  
[IP_ADDRESS]  ECG assessment  ......................................................................78  
7.2.4  Patient preferences questionnaire  .....................................................79  
7.2.5  Laboratory assessments  ....................................................................79  
[IP_ADDRESS]  Type of laboratory ...................................................................79  
[IP_ADDRESS]  Laboratory tests  .......................................................................[ADDRESS_422920] -STUDY TREATMENT / MEDICAL 
CARE  ..........................................................................................................................81  
8.1 Study completion as per protocol .................................................................81  
8.2 Premature withdrawal from study  ................................................................81  
8.3 Premature termination or suspension of the study ........................................82  
8.4 Medical care of subjects after study completion / withdrawal from 
study ..............................................................................................................[ADDRESS_422921] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 9/[ADDRESS_422922] 2017 -004642 -20 
Doc No D- 18.160 
 
9.3.1  Reporting of pregnancy ....................................................................88  
9.3.2  Follow-up of pregnancy ....................................................................88  
9.4 Study safety monitoring  ................................................................................88  
10 STATISTICAL METHODS  .......................................................................................88  
10.1  Analysis sets  .................................................................................................88  
10.1.1  Screened Analysis Set  .......................................................................88  
10.1.2  Full Analysis Set ...............................................................................89  
10.1.3  Per-Protocol Set ................................................................................89  
10.1.4  Safety Set  ..........................................................................................89  
10.1.5  Treatment Withdrawal Set  ................................................................89  
10.1.6  Pharmacokinetic Analysis Set  ..........................................................89  
10.1.7  Patient Preferences Analysis Set  .......................................................89  
10.1.8  Usage of the analysis sets  .................................................................89  
10.2  Variables  .......................................................................................................90  
10.3  Description of statistical analyses  .................................................................90  
10.3.1  Analysis of the primary and secondary efficacy variables  ...............90  
[IP_ADDRESS]  Overall testing strategy  ............................................................90  
[IP_ADDRESS]  Hypotheses and statistical model ............................................93  
[IP_ADDRESS]  Handling of missing data  .........................................................93  
[IP_ADDRESS]  Supportive/sensitivity analyses ...............................................93  
10.3.2  Analysis of other efficacy variabl es ..................................................94  
10.3.3  Analysis of the safety variables  ........................................................94  
10.3.4  Analysis of ph armacokinetic variables  .............................................95  
10.3.5  Subgroup analyses ............................................................................96  
10.3.6  Analysis of the patient preferences variable  .....................................96  
10.4  Interim analyses  ............................................................................................96  
10.5  Sample size  ...................................................................................................96  
11 DATA HANDLING  ....................................................................................................98  
11.1  Data collection  ..............................................................................................98  
11.2  Maintenance of data confidentiality  .............................................................99  
11.3  Database management and quality control  ...................................................99  
12 PROCEDURES AND GOOD CLINICAL PRACTICE  ...........................................100  
12.1  Ethics and Good Clinical Practice  ..............................................................100  
12.2  Independent Ethics Committ ee / Institutional Review Board  ....................100  
12.3  Informed consent ........................................................................................101  
12.4  Compensation to subjects and investigators ...............................................102  
12.5  Protocol adherence/compliance  ..................................................................[ADDRESS_422923] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 10/[ADDRESS_422924] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 11/[ADDRESS_422925]© .......................................................................................119  
Appendix 5  Insomnia Severity Index©.........................................................................120  
Appendix 6  Sheehan Disabili ty Scale© ........................................................................121  
Appendix 7  Benzodiazepi[INVESTIGATOR_42831] ............................122  
Appendix 8  Sleep Diary  ...............................................................................................123  
Appendix 9  Patient Global Assessment of Disease Severity and Patient Global Impression of Change, daytime symptoms ..............................................125
 
Appendix 10  Patient Global Impression of Severity (PGI- S) and Patient Global 
Impression of Change (PGI-C), night- time symptoms  ............................126  
Appendix 11  Insomnia Daytime Symptoms and Impacts Questionnaire  ......................127  
Appendix 12  Epworth Sleepi[INVESTIGATOR_7110]©.......................................................................131  
Appendix 13  Mini Mental State Examination© .............................................................[ADDRESS_422926] Udy in in Somnia (PAUSe)  ....................................[ADDRESS_422927] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 12/[ADDRESS_422928]  
AHI  Apnea/hypopnea index 
ALT   Alanine aminotransferase 
AST   Aspartate aminotransferase 
AV  Atrioventricular  
BMI   Body mass index 
BP  Blood pressure 
bpm  Beats per minute  
BRA   Benefit -risk assessment  
BWSQ   Benzodiazepi[INVESTIGATOR_223108]  (US) 
CNS   Central nervous system 
CR  Controlled- release  
CRA   Clinical Research Associate  
CRO   Contract Research Organization  
CSR   Clinical Study Report  
C-SSRS©  Columbia Suicide Severity Rating Scale© 
CV%   Coefficient of variation  
CYP   Cytochrome P450 
DB  Double-blind 
DCE   Discrete Choice Experiment  
DoA  Delegation of Authority 
DORA  Dual orexin receptor antagonist 
DSM -[ADDRESS_422929] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 13/[ADDRESS_422930] 2017 -004642 -20 
Doc No D- 18.160 
 
ECG   Electrocardiogram/graphy  
eCRF   Electronic Case Report Form  
EDS   Excessive daytime sleepi[INVESTIGATOR_223109]-of-Double-Blind Treatment  
EOS   End-of-Study 
EOT   End-of-Treatment  
ESS©  Epworth Sleepi[INVESTIGATOR_7110]© 
FAS  Full Analysis Set 
FDA   Food and Drug Administration 
GABA   Gamma -aminobutyric acid 
GCP   Good Clinical Practice  
HR  Heart rate  
IB  Investigator’ s Brochure  
ICF  Informed consent f orm 
ICH  International Council for Harmonisation 
IDMC   Independent Data Monitoring Committee 
IDSIQ   Insomnia Daytime Symptoms and Impacts Questionnaire  
IEC  Independent Ethics Committee 
IRB  Institutional Review Board  
IRT  Interactive Response Technology 
ISAC   Independent Statistical Analysis Center  
ISB  Independent Safety Board  
ISF  Investigator Site File  
ISI©  Insomnia Severity Index© 
LPS  Latency to Persistent Sleep  
MAR   Missing at random 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 14/[ADDRESS_422931] 2017 -004642 -20 
Doc No D- 18.160 
 
MedDRA   Medical Dictionary for Regulatory Activities  
MINI©  Mini International Neuropsychiatric Interview© 
MMSE©  Mini Mental State Examination© 
NOAEL   No-observed -adverse -effect level  
PAUSe   PAtient Preferences StUdy in InSomnia  
PD  Pharmacodynamic(s)  
PGA-S  Patient Global Assessment of Disease Severity  
PGI-C  Patient Global Impression of Change 
PGI-S  Patient Global Impression of Severity  
PI  [INVESTIGATOR_168834](s)  
PLMAI   Periodic limb movement with arousal index  
PPS  Per-Protocol Set 
PSG  Polysomnography 
PT  Preferred Term  
QS  Quality System 
QTc  Corrected QT interval  
QTcB   QT interval corrected with Bazett ’s formula  
QTcF   QT interval corrected with Fridericia’ s formula  
REM   Rapid eye movement 
RSI  Reference Safety Information  
RUT   Random utility theory 
SAE   Serious adverse event  
SAP  Statistical Analysis Plan  
SD  Standard deviation 
SDS©  Sheehan Disability Scale© 
SIV  Site Initiation Visit 
sLSO   Subjective Latency to Sleep Onset  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 15/[ADDRESS_422932]   Upper limit of normal 
USPI   [INVESTIGATOR_42836](s)  
WASO   Wake After Sleep Onset  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 16/[ADDRESS_422933] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 17/[ADDRESS_422934] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 18/[ADDRESS_422935] -541468 in subjects with 
insomnia disorder duri ng treatment and upon treatment 
discontinuation. 
DESIGN  Multi -center, double -blind, randomized, placebo -controlled, 
parallel -group, Phase 3 study. 
PHASES  The study comprises the following 3 phases: the screening phase, the 
treatment phase, and the safety  follow-up phase. 
The screening phase start s with the signature [CONTACT_223203] 1 and ends at Randomization ( Visit 4 ), provided the 
subject fulfills all the eligibility criteria. It includes the Screening 
period and the Run- in period. The screening phase lasts 20 to 31 days.  
The Screening period  starts with Visit 1 and ends at  Visit 2. During 
the Screening period, the investigator verifies  eligibility criteria and 
eligible subjects perform a one -night polysomnography (PSG) 
assessment. The Screening peri od last s [ADDRESS_422936] the minimum number of eDiary entries (i.e., 7  days) between 
Visit 1 and Visit 2.  
The Run-in period  starts with Visit 2 and ends at Randomization 
(i.e., Visit 4). At Visit [ADDRESS_422937] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 19/[ADDRESS_422938] s 13 to 24 days, to allow collection of the minimum number 
of eDiary entries (i.e., 7 days), perform 2 PSG nights at Visit 3, and 
receive the eligibility confirmation from the PSG central reader.   
The double -blind (DB) treatment phase  lasts 3 months. It starts at 
Randomization (V isit 4).  DB study treatment is taken daily. A safety 
telephone call is performed at Visit [ADDRESS_422939] info rmation about 
adverse events (AEs) and concomitant medications. Sleep parameters of each subject are objectively assessed with 2  
consecutive PSG 
nights at Visit 6 and Visit 8. A safety visit without PSG night will be 
performed at Visit 7.  An eDiary is comp leted every day  during the 
treatment phase. 
End-of-Double -Blind -Treatment (EO DBT) is reached in the 
second morning of V isit 8. 
The safety follow -up phase  starts after EO DBT. It consists of a 
single -blind placebo run- out period of 7 days and a safety follow -up 
period.  
The Run-out period  starts in the evening of Visit 9. Visit 9 consists 
of one PSG night on single -blind placebo treatment. V isit 9 is 
followed by 6 days at home  with single -blind placebo treatment. The 
eDiary is completed every day during the Run- out period. The end of 
the R un-out period ( End-of-Treatment  [EOT ]) is reached after all 
visit a ssessments have been performed at Visit 10. 
The Safety follow -up period starts after EOT  and ends [ADDRESS_422940] dose of DB study treatment intake for subjects that are not 
enrolled in the ID-078A303 extension study. 
Subjects who complete DB study treatment and the Run -out period 
are eligible to enter the ID -078A303 extension study (if approved by 
[CONTACT_223146] / Institutional Review Boards ). For these subjects, the 
safety follow -up period ends on the date of enrolment into ID -
078A303. End-of-Study  (EOS)  for an individual subject is defined as the date 
of the 30- day follow -up telephone call (V isit 11) or the date of 
enrolment into the ID -078A303 extension study. If a subject is 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 20/[ADDRESS_422941] visit.  
SITE(S)  / 
COUNTRY(IES)  The study will be conducted at  approximately 75 sites in 
10 countries. 
SUBJECTS / 
GROUPS  Approximately [ADDRESS_422942] -541468, or to placebo, in a 1:1:1 ratio. Treatment 
allocation will be stratified by [CONTACT_42889] 2 categories: <  65 and ≥ 65 
years . Approximately 40% of subjects will be elderly subjects (≥ 65 
years old), of which approximately 5% will be above  75 years old.  
These percentages will be monitored by [CONTACT_223147]. 
INCLUSION 
CRITERIA  Criteria assessed at V isit 1: 
1. Signed informed consent prior to any study -mandated pr ocedure. 
2. Male or female aged ≥ 18 years.  
3. Insomnia disorder according to Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition ( DSM -5) criteria, as follows: 
3.1 The predominant complaint is dissatisfaction with sleep 
quantity or quality, associated with one (or more) of the 
following symptoms: 
• Difficulty initiating sleep.  
• Difficulty maintaining sleep, characterized by [CONTACT_223148].  
• Early -morning awakening with inability to ret urn to 
sleep.  
3.[ADDRESS_422943] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 21/[ADDRESS_422944] 2017 -004642 -20 
Doc No D- 18.160 
 
3.4 The insomnia is not better explained by [CONTACT_223149]- wake 
disorder (e.g., narcolepsy, a breathing -related sleep 
disorder, a circadian rhythm sleep- wake disorder, a 
parasomnia).  
3.5 The ins omnia is not attributable to the physiological effects 
of a substance (e.g., a drug of abuse, a medication). 
3.[ADDRESS_422945] 3 months prior to Visit 1: 
3.7.1 ≥ 30 min to fall asleep, and 3.7.2 Wake time during sleep ≥ 30 min, and 
3.7.3 Subjective Total Sleep T ime (sTST) ≤ 6.5 h 
4. Insomnia S everity Index
© score ≥ 15. 
5. Ability to communicate well with the investigator, to understand 
the study requirements and, as judged by [CONTACT_093], to be alert and oriented to person, place, time, and situation. 
Criteria assessed at V isit [ADDRESS_422946] 3 nights out 
of 7 nights on the sleep diary completed at home between V isit 2 
and V isit 3: 
6.1 ≥ 30 min to fall asleep, and 6.2 Wake time during sleep ≥ [ADDRESS_422947] of ≤ 6.5 h 
7. Usual bedtime  
between 21:30 and 00:30 as reported on sleep 
diary completed between V isit 2 and V isit 3. 
8. Regular time in bed between 6 and 9 h as reported on sleep diary 
completed between V isit 2 and V isit 3. 
9. Meeting all the following sleep parameters on the 2 PSG  nights 
at Visit 3: 
9.1 Mean Latency to Persistent Sleep (LPS) ≥ 20 min (with 
neither  of the two nights < 15 min), and 
9.2 Mean Wake After Sleep Onset (WASO) ≥ 30 min (with 
neither  of the two nights < 20 min), and 
9.3 Mean Total Sleep Time (TST) < [ADDRESS_422948] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 22/[ADDRESS_422949] 2017 -004642 -20 
Doc No D- 18.160 
 
Criteria assessed at V isit 1, Visit 2, and Visit 4: 
10. For women of childbearing potential, the following are  required: 
• Negative serum pregnancy test (Visit 1). 
• Negative urine pregnancy test (V isit 2, Visit 4). 
• Agreement to use the contraception scheme as  required by 
[CONTACT_223150] [ADDRESS_422950] 
DB study treatment intake.  
EXCLUSION 
CRITERIA  Criteria assessed at V isit 1 
1. Body mass index below 18.5 or above 40.0 kg/m2. 
2. Any lifetime history of sleep -related breathing disorder, including 
chronic obstructive pulmonary disease and sleep apnea. 
3. Cognitive behavioral therapy (CBT)  for any indication is  allowed  
only if the CBT  started at least [ADDRESS_422951]  agrees to continue this CBT throughout the study. 
4. Self-reported  usual daytime nappi[INVESTIGATOR_007] ≥ 1 h per day, and ≥ 3 days 
per week.  
5. Acute or unstable psychiatric conditions (including but not 
restricted to anxiety disorder, major depression, bipolar disorder, schizophrenia, obsessive compulsive disorder, or depression ) that 
are diagnosed by [CONTACT_223151]© or that require pharmacological treatment for these 
disorders. N.B.: subjects with a history of major depressive 
disorder currently without a ny symptoms and not requiring 
treatment are eligible.  
6. Mini Mental State Examination© score < 25 in subjects 
≥ 50 years . 
7. Shift work within 2 weeks prior to the screening visit, or planned 
shift work during the study.  
8. Travel  across ≥ 3 time  zones within 2 weeks prior to the screening 
visit, or planned travel across ≥ [ADDRESS_422952] ’s safety or interfere with the 
study assessments.  
10. Treatment with central nervous system -active drugs prohibited by 
[CONTACT_223152] 5  half-lives of the respec tive drug (or 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 23/[ADDRESS_422953] 2017 -004642 -20 
Doc No D- 18.160 
 
2 weeks, whichever is longer) prior to V isit 1, including over -the-
counter medication and herbal medicines. 
11. Diagnosis of alcohol or substance use disorder within [ADDRESS_422954] 3 consecutive days. 
12. Heavy tobacco use (at least one pack of cigarettes a day or 
inability to refrain from  smoking during the night).  
13. Caffeine consumption ≥ [ADDRESS_422955] -541468. 
15. Known hypersensitivity or contraindication to drugs of the same 
class  as the study treatment or to any excipi[INVESTIGATOR_223111]. 
16. Not able or willing to stop treatment with moderate or strong 
cytochrome P450 (CYP)3A4 inhibitors, or treatment with 
moderate o r stron g CYP3A4 inducers, within at least  1 week prior 
to Visit 2.  
17. Not able or willing to stop consumption of grapefruit, Seville 
(bitter) oranges or  juices from those fruits within at least  1 week 
prior to Visit 2.  
Criteria assessed at PSG visit between Visit 1 and Visit 2  
18. Periodic limb movement disorder with arousal index  (PLMAI)  
≥ 15/h (assessed on the 1st PSG night ), restless legs syndrome, 
circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.  
19. Apnea/hypopnea index ≥  15/h according to American Academy 
of Sleep Medicine criteria or event associated  with blood oxygen 
saturation  level  by [CONTACT_406] (SpO
2) < 80%, as assessed on 
the 1st PSG  night. 
Criteria assessed at V isit 1 and V isit 3 
20. Aspartate aminotransferase and/or alanine aminotransferase > 2 × 
upper limit of normal (ULN)  and/or direct bilirubin >  1.5 × ULN.  
21. Severe renal impairment: known or defined as estimated 
creatinine  clearance  < 30 mL/min/1.[ADDRESS_422956] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 24/[ADDRESS_422957] results deviating from the 
normal range  to a clinically relevant extent as per judgment of the 
investigator.  
23. Any of the following conditions related to ECG abnormalities : 
• A prolonged QT interval corrected with Bazett ’s formula 
(QTcB) or QT interval corrected with Fridericia ’s formula 
(QTcF) (greater than 450 ms). If QTcB or QTcF is greater 
than [ADDRESS_422958] is not eligible.  
• A history of additional risk factors for torsade de pointes (e.g., 
heart failure, hypokalemia, family history of long QT 
syndrome). 
• ECG with clinically signi ficant atrioventricular (AV) 
conduction disturbance (e.g., second- or third -degree AV 
block), sick sinus syndrome, bradycardia (resting pulse 
< 40 bpm), or accessory by[CONTACT_59585] ( e.g., Wolff-Parkinson-
White).  
Criteri on assessed at V isit 1, Visit 2, Visit 3 and Visit 4  
24. Any of the following conditions related to suicidality:  
• Any suicidal ideation with intent, with or without a plan, at 
screening, i.e., answering “Yes” to questions 4 or 5 on the 
suicidal ideation section of the lifetime (Visit 1) and visit 
(Visit 2, Visit 3, Visit 4 ) version of the Columbia Suicide 
Severity Rating Scale© (C-SSRS©). 
• History of suicide attempt on the suicidal behavioral section 
of the lif etime version of the C- SSRS© (Visit 1).  
Criteria assessed at Visit 1, PSG visit between Visit [ADDRESS_422959] s: pregnant, lactating or planning to become 
pregnant during projected duration of the study. 
26. Positive urine drug test (for benzodiazepi[INVESTIGATOR_1651], barbiturates, 
cannabinoids , opi[INVESTIGATOR_858], amphetamines, phencyclidine or cocaine) 
or presence of alcohol in exhaled breath as detected by 
[CONTACT_215202].  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 25/[ADDRESS_422960] -541468- matching placebo will be administered orally, once 
daily in the evening during the single -blind run- in period, the DB 
treatment period and the single-blind run-out period. 
ENDPOINTS  Primary efficacy endpoints  
The primary efficacy endpoints of this study are defined as: 
• the change from baseline to Month 1 in WASO ( sleep 
maintenance)  
• the change from baseline to Month 3 in WASO  
• the change from baseline to Month 1 in LPS (sleep onset) 
• the change from baseline to Month 3 in LPS  
Baseline is defined as mean of the 2 PSG nights at Visit 3 . Month 1 
and Month 3 are defined as the mean of the  2 PSG nights at Visit 6 
and Visit 8, respectively.  
LPS (min) is the time from start of recording to the beginning of the 
first continuous 20 epochs (i.e., 10 min) scored as non- awake, i.e., 
epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), s leep 
stage 3 (slow wave sleep) or REM, as determined by [CONTACT_63175].  
WASO is the time (min) spent awake after onset of persistent sleep 
until lights on, as determined by [CONTACT_63175]. 
Secondary efficacy endpoints  
The secondary efficacy endpoints of this study are defined as:  
• the change from baselinea to Month 1b in sTST.  
• the change from baselinea to Month 3c in sTST.  
• the change from baselinea to Month 1b in Insomnia Daytime 
Symptoms and Impacts Questionnaire (IDSIQ) sleepi[INVESTIGATOR_223112]. 
• the change from baselinea to Month 3c in IDSIQ sleepi[INVESTIGATOR_223112].  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 26/[ADDRESS_422961] 2017 -004642 -20 
Doc No D- 18.160 
 
a Baseline is the mean value based on the screening sleep diary  / 
IDSIQ  entries performed at home  in the [ADDRESS_422962] PSG at Visit 3.  
b ‘Month 1’ is the mean value based on the sleep diary / IDSIQ entries 
performed at home in the [ADDRESS_422963] PSG 
at Visit 6.  
c ‘Month 3’ is the mean value based on the sleep diary / IDSIQ entries 
performed at home in the [ADDRESS_422964] PSG at Visit 8. 
Safety endpoints  
In addition to the standardized collection of AEs, safety data specific to insomnia and its treatment will be assessed as follows:  
• 
Withdrawal effects (physical dependence) upon treatment 
discontinuation will be assessed based on the changes from last assessment on DB treatment (Visit 8, 2
nd morning) to run -out 
period in the Benzodiazepi[INVESTIGATOR_223144] (BWSQ) total score ( Visit 9 and Visit 10), the 
occurrence of relevant AEs and marked ECG abnormalities.  
• Rebound insomnia will be assessed based on objective sleep 
parameters (WASO, LPS, and TST) at Visit 9 as compared to 
Visit 3. It will also be assessed using subjective sleep parameters (subjective WASO [sWASO], subjective Latency to Sleep Onset [sLSO], and sTST) from run-out period as compared to baseline. 
• Next -day residual effects will be assessed based on changes from 
baseline (Visit 3) to Month 1 and Month 3 in: 
– Coding sub- test
©  
– Sheehan Disability Scale© (SDS©) 
– Scores on the visual analog scale (VAS; mm)  
• Serious adverse events up to 30 days after DB study treatment 
discontinuation or until enrollment into the extension study. 
• Treatment -emergent AEs (TEAEs) up to 30 days after DB study 
treatment discontinuation or until enrollment into the extension 
study. 
• AEs leading to premature discontinuation of the DB study 
treatment.  
• AEs of special interest (AESIs) after adjudication by [CONTACT_223153] (ISB): 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 27/[ADDRESS_422965] 2017 -004642 -20 
Doc No D- 18.160 
 
– narcol epsy-like symptoms (i.e. , excessive daytime sleepi[INVESTIGATOR_008] 
[EDS ], cataplexy and comp lex sleep behavior events 
including hallucinations/sleep paralysis)  
– suicide/self -injury. 
• Change from baseline (Visit 3) to Month 1 (Visit 6) and Month 3 
(Visit 8) in vital signs (mean of the 2 PSG nights in systolic and 
diastolic blood pressure [BP] and pulse rate). 
• Change from baseline (Visit 1 ) to Month 3 (Visit 8) in body 
weight.  
• Marked ECG abnormalities on DB study treatment.  
• Change from baseline (Visit 3) to Month 3 (Visit 8) and the end 
of run -out (Visit 10) in ECG variables.  
• Marked laboratory abnormalities on DB study treatment.  
• Change from baseline (Visit 3) to Month 1 (Visit 6) and Month 3 
(Visit 8) in laboratory variables. 
• Occurrence of suicidal ideation and/or behavior on DB study 
treatment based on C -SSRS©. 
ASSESSMENTS  Refer to the schedule of assessments in  Table 1. 
STATISTICAL 
METHODOLOGY  Analysis of the primary and secondary efficacy endpoints  
The Type I error rate will be controlled for the testing of multiple null 
hypotheses associated with the two primary endpoints (LPS and 
WASO) and two other endpoints (sTST and IDSIQ) assessed at 1 and 3 months of treatment, and the two dose levels included in this study, i.e., 25 mg and 50 mg. 
The eight statistical null hypotheses associated with the primary 
efficacy endpoints are: 
Sleep maintenance:  
• H1WASO : Higher Dose – Placebo = 0 for WASO at Month 1 
• H2WASO : Higher Dose – Placebo = 0 for WASO at Month 3 
• H3WASO : Lower Dose – Placebo = 0 for WASO at Month 1 
• H4WASO : Lower Dose – Placebo = 0 for WASO at Month 3 
Sleep onset:  
• H1LPS: Higher Dose – Placebo = 0 for LPS at Month 1 
• H2LPS: Higher Dose – Placebo = [ADDRESS_422966] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 28/[ADDRESS_422967] 2017 -004642 -20 
Doc No D- 18.160 
 
• H3LPS: Lower Dose – Placebo = 0 for LPS at Month 1  
• H4LPS: Lower Dose – Placebo = 0 for LPS at Month 3 
The eight statistical null hypotheses associated with the secondary 
efficacy endpoints are: 
Sleep quantity: 
• H1sTST: Higher Dose – Placebo = [ADDRESS_422968] at Month 1 
• H2sTST: Higher Dose – Placebo = [ADDRESS_422969] at Month 3 
• H3sTST: Lower Dose – Placebo = [ADDRESS_422970] at Month 1 
• H4sTST: Lower Dose – Placebo = [ADDRESS_422971] at Month 3 
Next -day performance: 
• H1IDSIQ: Higher Dose – Placebo = 0 for IDSIQ sleepi[INVESTIGATOR_223114] 1 
• H2IDSIQ: Higher Dose – Placebo = 0 for IDSIQ sleepi[INVESTIGATOR_223114] 3 
• H3IDSIQ: Lower Dose – Placebo = 0 for IDSIQ sleepi[INVESTIGATOR_223114] 1 
• H4IDSIQ: Lower Dose – Placebo = 0 for IDSIQ  sleepi[INVESTIGATOR_223114] 3 
where ‘Higher Dose ’, ‘Lower Dose ’, and ‘Placebo ’ represent the 
mean change from baseline for the given endpoint (WASO, LPS, 
sTST or IDSIQ sleepi[INVESTIGATOR_223115]) and time point (Month 1 or 
Month 3) for the [ADDRESS_422972] the alternative hypothesis: that ACT -
541468 improves WASO/LPS/sTST/ IDSIQ sleepi[INVESTIGATOR_223116] (25 or 50 mg) and time point (Month 
1 or Month 3) co mpared to  placebo.  
The order of testing and the alpha level applied to each null 
hypothesis will be based on the Bonferroni -based gatekeepi[INVESTIGATOR_223117] [Bretz  2009] , which will control the study -wise Type  I 
error at a two -sided 5% significance level. To account for the 
concurrent evaluation (multiple comparison) of two distinct endpoint 
categories (i.e., sleep maintenance and sleep onset) , a Bonferroni 
correction is applied. Both endpoint categories will be tested at half 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 29/[ADDRESS_422973] 2017 -004642 -20 
Doc No D- 18.160 
 
of the two -sided 5% significance level. This supports the sponsor ’s 
intention  to make a superiority claim versus  placebo for efficacy in 
either sleep maintenance and/or sleep onset . The remaining 
hypotheses will be tested following the gatekeepi[INVESTIGATOR_223118] [ADDRESS_422974] -541468 vs 
placeb o. The pre -specified proportion of alpha that will be distributed 
once a given null hypothesis (node) is rejected is shown on the arrow 
in the directed graph. If a certain null hypothesis cannot be rejected, the alpha level used for that test is absorbed a
t that node and not 
distributed further. 
The main analysis will be performed using the FAS.  
A longitudinal data analysis method (i.e., linear mixed effects model) 
will be used for the analysis of change from baseline in WASO, LPS, sTST, and IDSIQ scores, s eparately.  All available data, regardless of 
occurrence of intercurrent events (e.g., study treatment 
discontinuation, the use of prohibited medication) , will be included 
in the model. 
Analysis of the safety endpoints  
Adverse events:  The number (%) of subj ects experiencing a TEAE 
(including serious adverse events, AE SIs after adjudication by [CONTACT_223154], and AEs leading to premature discontinuation of the DB study 
treatment) will be summarized by [CONTACT_136493]/or 
Preferred Term, and maximum intensity.  
Laboratory data:  Observed values and changes from baseline to 
Month 1 and Month 3 in both hematology and blood chemistry 
laboratory parameters will be summarized. The number (%) of 
subjects having a marked laboratory abnormality during DB study 
treatment will be tabulated.  
Vital signs  and weight:  Observed values and changes from baseline 
to Month 1 and Month 3 in vital signs (mean of the two PSG nights 
in systolic and diastolic BP and pulse rate) and observed values and 
changes from baseline to Month 3 in body weight will be 
summarized.  
Electrocardiograms:  Observed values and changes from baseline to 
Month 3 for each ECG parameter (QTcB, QTcF, heart rate, PR, QRS) 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 30/[ADDRESS_422975] 2017 -004642 -20 
Doc No D- 18.160 
 
will be summarized. The number (%) of subjects with a marked ECG 
abnormality during DB study treatment will be tabulated . 
Withdrawal symptoms:  The BWSQ total score will be summarized 
using descriptive statistics for the observed values and changes from 
the last assessment on DB treatment (Visit 8, 2nd morn ing) to the 
beginning and the end of the treatment withdrawal period (in the 
morning at Visit 9 and at Visit 10, respectively). The number (%) of 
subjects having, separately, an AE and a marked ECG abnormality 
during the treatment withdrawal period will be  tabulated.  
Insomnia rebound effect:  The changes from baseline to the treatment 
withdrawal period (Visit 9, run- out) in objective sleep parameters 
(WASO, LPS, and TST) will be summarized using descriptive 
statistics. The changes from baseline (mean value b ased on the 
screening sleep diary entries performed at home in the [ADDRESS_422976] PSG at Visit 3) to the treatment 
withdrawal period (after PSG night at Visit 9) in subjective sleep 
parameters (sWASO, sLSO, and sTST) will be summari zed using 
descriptive statistics.  
Next-day residual effects:  Observed values and changes from 
baseline to Month [ADDRESS_422977]©, SDS©, and 
VAS scores (mm) assessing morning sleepi[INVESTIGATOR_008], daytime alertness, 
and daytime ability to function, w ill be summarized.  
C-SSRS©: Number (%) of subjects with suicidal ideation, suicidal 
behavior, and/or self -injurious behavior without suicidal intent based 
on the C -SSRS© during DB treatment will be tabulated. Shifts from 
baseline showing any changes in sui cidal ideation and suicidal 
behavior during DB treatment will also be provided. 
STUDY 
COMMITTEES  An Independent Data Monitoring Committee (IDMC) will have 
overall responsibility for safeguarding the interests of subjects by 
[CONTACT_223156] , and making 
appropriate recommendations based on the reported data . This will  
ensure that the study is being conducted to the highest scientific and 
ethical standards. The IDMC  will be fully operational prior to the 
enrollment of the first subject into the study. The composition and 
operation of the IDMC is described in the IDMC charter. 
An ISB will review and adjudicate in a blinded manner AE SIs, i.e., 
narcolepsy -like symptoms (i.e., EDS, cataplexy and complex sleep 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 31/[ADDRESS_422978] 2017 -004642 -20 
Doc No D- 18.160 
 
behavior events inc luding . hallucinations/sleep paralysis), or 
suicide/self -injury . The composition and operation of the ISB is 
described in the ISB charter.  
SUB- STUD Y A sub -study will be performed to collect patie nt preference s data.  
The Discrete Choice E xperiment methodology aims to collect 
preferences for selected treatment outcomes in a subgroup of at least 
360 subjects in [LOCATION_003] and [LOCATION_013]  that are part of the approximately 
900 subjects enrolled in the ID -078A301 study,  using the 
questionnaire for the PAtient Preferences StUdy in InSomnia 
(PAUSe) developed by [CONTACT_42944].  
STUDY 
EXTENSION  Subjects who completed the study until EOT  will have the possibility 
to participate in the extension study ID -078A303. The 9 -month ID -
078A303 study will be available at each site and subjects will be 
treated for up to 12 months overall (i.e., including the treatment 
period of the confirmatory trial).  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 32/[ADDRESS_422979] 2017 -004642 -20 
Doc No D- 18.160 
 
PROTOCOL 
1 BACKGROUND 
1.1 Insomnia disorder 
1.1.1 Definition  
The definition of insomnia disorder used in the protocol is the one described in the 
Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM -5) 
[APA 2013]:  
“Insomnia disorder  is a predominant complaint of dissatisfaction with sleep quantity or 
quality , associated with difficulty initiating or maintaining sleep, or early morning 
awakening. Furthermore, the sleep disturbance is associated with significant social or functional distress or impairment. Sleep difficulty occurs at least [ADDRESS_422980] 3 months, and occurs despi[INVESTIGATOR_42842]. The insomnia (a) is not better explained by, and does not occur exclusively during the course 
of another sleep -wake disorder, (b) it is not attributable to the physiological effect of a 
substance, and (c) is not explained by [CONTACT_3252] -existing mental disorders or medical conditions.” 
1.1.[ADDRESS_422981] that 
30% or more of the general population complain of sleep disruption and approximately 10% of the general population have complaints of sleep disruption with associated symptoms of distress or dayti me functional impairment consistent with the diagnosis of 
insomnia disorder [NIH 2005, Roth 2007] . Insomnia symptoms (difficulties initiating 
sleep, early -morning awakenings, and dissatisfaction with sleep) increase with age.  Factors 
associated with aging  and not with age per se, such as depressed mood, respi[INVESTIGATOR_037], poor perceived health and ph ysical disability  are associated with the decrease 
in ability to sleep [Ohayon  2001].   
Insomnia disorder result s in difficulty falling asleep or difficulty maintaining sleep, 
characterized by [CONTACT_341787], or early -morning 
awakenings. Diff iculty maintaining sleep is the most common problem among patients 
with insomnia, occurring in approximately two- thirds of them [Neubauer  2014] . Studies 
have shown that the most common symptoms are combined difficulties to  both fall and to 
stay asleep [Hohagen 1994] . Elderly patients are more likely to suffer from chronic 
insomnia characterized by [CONTACT_223158] , rather  than difficulty initiating 
sleep [McCall  2004].  
Insomnia is associated with impairment in cognitive functioning, daytime fatigue, 
increased accident risk, and difficulties in interpersonal relationships [Balter  1991, 
Ancoli- Israel  1999, Rosenthal 1993, Zammit 1999, Fortier -Brochu  2014] . Insomnia 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 33/[ADDRESS_422982] 2017 -004642 -20 
Doc No D- 18.160 
 
increases utilization of medical care [Simon  1997, Léger  2002, McCall  2004] , has been 
correlated with chronic health issues and perceptions of poor health [Balter  1991, 
Ancoli- Israel  1999, Rosenthal 1993, Zammit 1999, Fortier -Brochu 2014] , and in elderly 
subjects may also precipi[INVESTIGATOR_223119] [McCall  2004] . Numerous studies have shown an 
association between insomnia and psychiatric disorders, specifically depression, anxiety, and other significant mental health conditions [ Ford  1989, Benca 2004].   
1.1.3 Treatment  
The current standards of care encompass non-pharmacological therapi[INVESTIGATOR_42843] [Schutte-Rodin 2008].  
Non-pharmacological (psychological and behavioral) standard -of-care therapi[INVESTIGATOR_42844] a variety of treatment methods, such as  cognitive behavioral therapy 
(CBT), stimulus control and relaxation training [Schutte-Rodin 2008] . Sleep hygiene 
therapy is often added to these treatment modalities.  
Prescription sleep medications (hypnotics) indicated for the treatment of insomnia include benzodiazepi[INVESTIGATOR_1651], non- benzodiazepi[INVESTIGATOR_42845], melatonin 
agonists, the orexin receptor antagonist suvorexant, and low-dose doxepin.  
Benzodiazepi[INVESTIGATOR_215159] a class of medications that bind to multiple gamma -aminobutyric acid 
(GABA) type A receptor subtypes [Lieberman  2007] . Drugs in this class, which includes 
flurazepam, temazepam, trialozam, estazolam, and quazepam, were previously commonly 
prescribed for insomnia. While the efficacy of these medications has been well documented, their usefulness is limited by [CONTACT_215209] (e.g., 
morning or next -day hangover), cognitive impairment (including anterograde amnesia), 
motor dyscoordination, abuse liability , and dependence [Holbrook 2000, Buscemi  2007] . 
Benzodiazepi[INVESTIGATOR_223121]: they prolong stage 2 sleep and may slightly reduce the relative amount of rapid eye movement (REM) sleep [Treat  Guidel Med  Lett 2009] . Their use has been associated with tolerance development 
and rebound insomnia upon withdrawal of medication [ Kales  1978, Petursson 1981] .  
Non-benzodiazepi[INVESTIGATOR_215161] a more targeted action on one 
or more GABA type A receptor subtypes , but the availability of these treatments highly 
varies across  regions . Zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_215162]- release (CR) and zaleplon show 
affinity for the alpha -1 receptor subtype, while eszopi[INVESTIGATOR_223122] -2 
and - 3 receptor subtypes [Nutt 2006 ]. All of these drugs reduce latency to sleep onset, but 
zolpi[INVESTIGATOR_223123] (WASO), reflecting an improvement in sleep maintenance [Ambien
® USPI , 
Lunesta® USPI ]. Although they have less impact on sleep architecture, possibly by [CONTACT_223159], the drugs in this group have similar adverse effects as the 
benzodiazepi[INVESTIGATOR_1651]. I n 2007 the US F ood and Drug Administration (FDA)  requested that all 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 34/[ADDRESS_422983] labeling to include stronger lan guage related to potential risks. These risks include severe allergic reactions 
(i.e., anaphylaxis) and complex sleep -related behaviors, which may include sleep-driving 
[FDA  2007].  
Newer hypnotics that do not act at the GABA receptor have been developed. The melatonin receptor agonist ramelteon is approved for insomnia in the US and in Japan, but not in Europe. Ramelteon reduces sleep latency and increases Total Sleep T ime (TST ), but has 
no effect on WASO [Kuriyama  2014] , making it an inappropriate treatment for people with 
sleep maintenance problems [Simpson 2008 ]. Ramelteon is devoid of next -day residual 
effects, withdrawal or rebound insomnia and does not appear to be associated with abuse liability.  
Suvorexant is an oral dual orexin receptor antagonist (DORA) that was approved in the 
[LOCATION_003], Japan and Australia  for the treatment of insomnia characterized by [CONTACT_341788]/or sleep maintenance. Suvorexant is contraindicated in patients with narcolepsy. Next -day effects, including impaired dr iving performance, have been reported 
at 20 mg [Belsomra
® USPI ]. Next -day residual effects might be related to the long half -
life (t ½ = 12 hours) of suvorexant [Citrome  2014] . Rebound insomnia or withdrawal signs 
upon drug discontinuation were not observed in clinical trials [ Herring  2016].  
Use of sleep medications increases with age and is highest in the elderly [Ohayon 2002, 
Ohayon 2010] . Despi[INVESTIGATOR_223124], non -benzodiazepi[INVESTIGATOR_341777] . 
1.1.[ADDRESS_422984] -line treatment for insomnia disorder 
[Schutte-Rodin 2008 ]. However, this may not be the ideal course of treatment for all 
patients. Many patients with insomnia are not interested in CBT, and when they are, access to CBT may be limited by [CONTACT_341789][INVESTIGATOR_42848], and 
the fact that CBT is time -consuming, costly, and its reimbursement is highly challenging 
[Pi[INVESTIGATOR_42849] 2007, Schutte-Rodin 2008] .  
Insomnia disorder is a chronic disease and currently available treatments are limited to short- term use with the exception of eszopi[INVESTIGATOR_42850] (in the US). Caution and 
dose reduction are also often advised in the elderly. Pharmacological treatments that address sleep onset problems alone do not provide relief to people with sleep maintenance difficulties, and treatments indicated fo r those with sleep maintenance problems may be 
associated with risks of cognitive impairment, postural instability, or next- day residual 
sedation that may impair driving [Neubauer  2014 ]. Moreover, the use of benzodiazepi[INVESTIGATOR_223126] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 35/[ADDRESS_422985] 2017 -004642 -20 
Doc No D- 18.160 
 
[McCall  2004] leading to hip and femur fractures, increased disability, and use of 
healthcare resources.  
Overall, there is a need for a long -term pharmacological treatment for insomnia disorder 
that addresses the most prominent and pressing symptoms of insomnia without negatively impacting next-day functioning.  
1.2 Study treatment : ACT-541468 
1.2.1 The orexin system  
The orexin system is involved in the regulation of sleep and arousal by [CONTACT_223160] (CNS) and is currently being targeted in the development of new therapi[INVESTIGATOR_215173]. 
The neuropeptides orexin- A and orexin -B are synthesized in the lateral hypothalamic areas 
[de Lecea 1998]  and activate the orexin -1 and orexin- 2 receptors [Kilduff 2000] . Nerve 
fibers from orexin neurons make projections to the basal forebrain, corticolimbic 
structures, and brainstem, particularly to those regions related to waking and regulation of sleep [Hagan  1999, Sakurai  2007] . Infusing exogenous orexins into cerebral ventricles in 
rats leads to enhanced behavioral activity, arousal, delayed onset of sleep, and maintenance of cortical activation [Hagan  1999, Samson  2010] . Orexin -producing neurons are active 
during wakefulness and fall quiet during sleep [Sakurai  2007] . Orexin -A levels in the 
cerebrospi[INVESTIGATOR_223127], being highest during active wake periods [ Zeitzer  2003, Desarnaud  2004].  
The absence of orexins is implicated in the genesis of narcolepsy, due to findings of low cerebral spi[INVESTIGATOR_341778]  [Mignot 2002]  and near-complete destruction of orexin neurons in post- mortem 
brains of patients with narcolepsy -cataplexy  [Thannickal 2000] , coupled with the 
observation of behavioral phenotypes consistent with narcolepsy in multiple animal models of orexin deficiency or dysfunction [ Lin 1999] .  

ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 36/[ADDRESS_422986] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 37/[ADDRESS_422987] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 38/[ADDRESS_422988] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 39/[ADDRESS_422989] -541468 
is well tolerated and efficacious in promoting sleep onset and/or sleep maintenance in 
subjects with insomnia disorder.  
1.3.[ADDRESS_422990] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 42/[ADDRESS_422991] -541468 in subjects with insomnia disorder 
during treatment and upon treatment discontinuation. 
3 OVERALL STUDY DESIGN AND PLAN 
3.1 Study design  
This is a 3 -month, multi- center, double -blind, randomized, pla cebo -controlled, 
parallel -group, Phase 3 study to assess the efficacy and safety of two  doses (25 mg and 
50 mg) of ACT -[ADDRESS_422992] -541468, 
or to placebo, in a 1:1:1 ratio. Treatment allocation will be stratified by [CONTACT_42889] 2 
categories: < 65 and ≥ 65 years. Approximately 40% of  subjects will be elderly subjects 
(≥ 65 years old), of which approximately  5% will be above 75 years old. These percentages 
will be monitored by [CONTACT_223161] (IRT) 
system . 
The study will be conducted at  approximately [ADDRESS_422993] ’s preferences will be performed, 
aiming to enroll at least  [ADDRESS_422994] been randomized in the 
ID-078A301 study.  
3.1.1 Study periods  
The study comprises the following 3 phases: the screening phase, the treatment phase , and 
the safety follow -up phase [see Figure 1]. 
[IP_ADDRESS] Screening phase  
The screening phase start s with the signature [CONTACT_28513] f orm (ICF) at Visit [ADDRESS_422995] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 43/[ADDRESS_422996] the minimum number of eDiary entries (i.e., 7  days) between Visit 1 and Visit 2.  
The Run -in period  starts with Visit 2 and ends at  Randomization (i.e., Visit 4). At Visit [ADDRESS_422997] s 13 to 24 days, to allow collection of the minimum 
number of eDiary entries (i.e., 7 days), perform 2  PSG nights at Visit 3, and receive the 
eligibility confirmation from the PSG central reader.  
[IP_ADDRESS] Treatment phase 
The DB treatment phase lasts 3 months. It starts at Randomization (Visit 4). DB study 
treatment is  taken daily. A safety telephone call is performed at Visit [ADDRESS_422998] are 
objectively assessed with 2 consecutive PSG nights  at Visit 6 and Visit 8. A safety visit 
without PSG night will be performed at Visit 7. An eDiary is completed every day  during 
the treatment  phase. 
End-of-Double -Blind -Treatment (EO DBT) is reached  in the second morning of Visit 8. 
[IP_ADDRESS] Safety follow-up phase 
The safety follow -up phase  starts after EO DBT. It consists of a single -blind placebo Run-
out period of 7 days and a Safety follow-up period.  
The Run-out period  starts in the evening of Visit 9. Visit 9 consists of one PSG night on 
single -blind placebo treatment. Visit 9 is followed by 6 days at home with single -blind 
placebo treatment. The eDiary is completed every day during the Run-out period. The end 
of the Run- out period  (End-of-Treatment [ EOT ]) is reached after all visit assessments have 
been performed at Visit 10. 
The Safety follow -up period starts after EOT  and ends [ADDRESS_422999] dose of DB study 
treatment intake for subjects that are not enrolled in the ID -078A303 extension study. 
Subjec ts who complete  DB study treatment and the Run- out period are eligible to enter the 
ID-078A303 extension study (if approved by [CONTACT_341790] / Institutional Review Boards [IECs/IRBs ]). For these 
subjects, the Safety follow -up period ends at the date of enrolment into ID-078A303. 
End-of-Study  (EOS) for an individual  subject is defined as the date of the 30 -day follow -
up telephone call (Visit 1 1, Day 115) or the da te of enrollment into the ID -078A303 
extension study. If a subject is prematurely discontinued from study treatment, EOS  is 
performed as planned on Day 115. If a subject withdraws consent and does not wish to 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 44/[ADDRESS_423000].  
The visit schedule and protocol -mandated procedures are performed according to the table 
of assessments [Table 1] and are described in Section  7. 
The overall study design is depi[INVESTIGATOR_123614] [ Figure 1]. 
Figure 1 Study design  
 
V = Visit; ▬ = polysomnography  nights; EODBT = End -of-Double -Blind -Treatment ; EOS  = End-of-Study; EOT = 
End-of-Treatme nt. 
 
3.1.[ADDRESS_423001] who 
does not decide to continue in the extension study, the study is completed with the EOS 
visit (safety follow -up telephone call at the end of follow -up) and the maximum duration 
of participation in  the study of this subject is expected to be approximately 5 months.  
Subjects who complete d the study until EOT  are eligible to participate in the extension 
study ID -078A303. After the completion of the Run-out period, the 9- month ID -078A303 
extension study will be available at each site, depending on health authority / IEC / IRB 
approval, and subjects will be treated for up to 12 months overall (i.e., including the treatment period of the confirmatory trial). For the subjects who decide to participate in the 
extension study, ID-078A301 is completed with the enrollment into ID-078A303. 

ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 45/[ADDRESS_423002] 2017 -004642 -20 
Doc No D- 18.160 
 
3.1.3 Sub- study – Patient Preferences 
A sub -study will be performed to collect patient preference s data.  
The Discrete Choice E xperiment (DCE) methodology aims  to collect preferences  for 
selected treatment outcomes in a subgroup of at least  360 subjects  in US A and [LOCATION_013] 
using the questionnaire for  the PAtient Preferences StUdy in InSomnia (PAUS e) developed 
by [CONTACT_42944].  
The questionnaire will present subjects with  the following treatment outcomes : 
• Time to fall asleep  
• Total time asleep  
• Next day impairment  
• Dizziness/grogginess during the daytime 
• Abnormal thinking and behavioral changes 
• Falls in the night  
• Dependence  
The design of the DCE questionnaire was carried out in steps 1 −3 below:  
1. Qualitative pi[INVESTIGATOR_2268] (n  = 24), where a mobile ethnography platform was used over a period 
of [ADDRESS_423003] patient experiences with insomnia in interactive sessions. This was 
followed by [CONTACT_37126] -to-face interviews with patients to further discuss themes that 
emerged during the 10 days of interactive sessions (completed).  
2. Qualitative pi[INVESTIGATOR_2268] (n  = 24), where face- to-face interviews were  conducted to ensure that 
the DCE outcomes and levels are associated with patients ’ experiences with (and 
expectations for) insomnia, and that the proposed survey accurately describes these 
outcomes in an easily understandable manner (completed).  
3. Quantitative pi[INVESTIGATOR_2268] (n  = 200), where an online survey was conducted to elicit preferences 
from patients , using the PAUSe  questionnaire. The data from the quantitative pi[INVESTIGATOR_341779]-
study.  
This sub- study has the following objectives: 1) To describe the stated preferences of 
insomnia disorder subjects within a clinical trial by [CONTACT_223164]; 2) To 
describe the impact of treatment on the preferences of insomnia subjects; 3) To de scribe 
the relationship between demographic, disease characteristics, previous medical history and elicited preferences among insomnia subjects. 
In addition, the results of the sub- study may contribute to the construction of  a 
patient -oriented benefit -risk assessment model.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 46/[ADDRESS_423004] 2017 -004642 -20 
Doc No D- 18.160 
 
3.2 Study design rationale 
3.2.1 Core study  
This is a multi- center, double -blind, randomized, placebo- controlled, parallel -group study.  
In accordance with the European Medicines Agency ( EMA ) guideline on medicinal 
products for the treatment of insomnia [EMA  2011]  and the FDA guideline for the clinical 
evaluation of hypnotic drugs [ FDA  1977] , the study includes a placebo as a comparator to 
support the evaluation of the efficacy of each dose of ACT -541468. Moreover, it is an 
acceptable approach for a non -life-threatening condition.  
A parallel -group design is a well -established study design to assess efficacy and safety in 
medical conditions, recommended by [CONTACT_21652] [EMA  2011, FDA  1977].  
The subjects will receive either a [ADDRESS_423005] -541468, or placebo DB 
study treatment. The doses to be tested for this study are based on a comprehensive set of 
data from Phase 1 and Phase 2 studies. A lower dose (10 mg), identified as the minimum 
effective dose in Phase 2, will be tested along with the 25 mg dose in another separate 
Phase 3 study (i.e., ID -078A302). A ll three doses selected for this p rogram have a favorable  
benefit -risk profile based on data collected so far during Phase [ADDRESS_423006]-541468 over a 3-month period, allowing full characterization of the benefit /risk ratio.  
The goal of the placebo run -in period is to increase the proportion of subjects in the clinical 
trial who will benefit due to taking active treatment, partly by [CONTACT_223165] ’ insomnia disorder and may reduce the impact of regression toward  the 
mean.  
A run -out of [ADDRESS_423007] -541468. The  duration of the run- out period is also compliant with the 
FDA guidance [FDA  1977] , stating that a minimum of 3 nights of placebo withdrawal is 
necessary to assess withdrawal effects. To assess withdrawal symptoms, AEs and ECG abnormalities will be collected during the 7 -day run -out period and subjects w ill complete 
the Benzodiazapi[INVESTIGATOR_42831] (BWSQ) at Visit [ADDRESS_423008] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 47/[ADDRESS_423009] 2017 -004642 -20 
Doc No D- 18.160 
 
3.2.2 Patient preferences sub -study  
Measuring patient preferences as an input to healthcare decisions has its foundations in two 
fields rel ated to behavioral decision making, namely ‘decision theory ’ and ‘ decision 
analysis ’. Research by [CONTACT_223166] . demonstrated that it was feasible to use decision 
analysis to understand individual treatment choices which were complicated by [CONTACT_341791] [Pauker  1981] . Increased understanding of individual 
values and preferences is critical for a number of reasons. Firstly, it enab les the 
development of patient -specific recommendations and reliable decision aids, which are 
helpful both for patients and for doctors in advising patients and their carers or families. Secondly, understanding of patients ’ preferences is the basis for shared decision-making, 
which in turn encourages patient compliance and health outcomes [Bowling 2001] . Lastly, 
understanding of preferences for health outcomes allows the design of transparent health policies, and informs resource allocation in healthcare, as these preferences can inform the judgment of cost- effectiveness of different treatments, for different patients [Coyle  2001] . 
DCEs  are a form of stated preference method used by [CONTACT_341792] -offs between an intervention’ s outcomes . They involve participants responding 
to a number of survey questions, in which they choose between alternative interventions, each described by a level of performance against the outcomes that influence choices. DCE 
has its microeconomic foundati on in random utility theory (RUT), assumin g that products 
can be valued in terms of their constituent outcomes and that respondents act in a utility 
maximizing manner, making choices contingent upon the outcome levels described in the 
exercise [Clark 2014, Tervonen 2017] . Consequently, the choice data can be analyzed 
using econometric methods compatible with RUT, which estimate how participants ’ utility 
is influenced by [CONTACT_223169] . DCEs are frequently used in healthcare 
to address a wide range of health policy -related concerns, including identifying the trade -
offs patients make when choosing between treatments, which can in turn be used to determine the probability that patients would pre fer one treatment or another [Bridges 
2011, Clark 2014].  
3.[ADDRESS_423010] into the study. The composition and operation of the IDMC is described in the IDMC charter. 
An ISB will review and adjudicate in a blinded manner A ESIs, i.e., narcolepsy -like 
symptoms ( EDS, cataplexy and complex sleep behavior events incl uding 
hallucinations/sleep paralysis), or suicide/self -injury . The composition and operation of the 
ISB is described in the ISB charter .  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 48/[ADDRESS_423011] population description 
This study will enroll adult and elderly  (≥ 18 years), male and female subjects with 
insomnia disorder  according to Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition ( DSM -5). For more details on inclusion and exclusion criteria, see 
Sections  4.3 and  4.4.  
Insufficient sleep quantity is defined in this study by [CONTACT_6270] -reported history of ≥ 30 min to 
fall asleep, of wake time during sleep ≥ [ADDRESS_423012] ( sTST) ≤ 6.[ADDRESS_423013] 3 months prior to the screening visit and on the sleep diary sleep data collected 
during the period between V isit 2 and V isit 3. They will also be validated by [CONTACT_223170]-based criteria collected from the V isit 3 PSG nights spent in a  sleep laboratory during 
the run- in. Poor Sleep Quality (SQ) is defined as  an Insomnia Severity Index© (ISI©) score 
≥ 15 at screening .  
4.2 Rationale for the selection of the study population 
In this study, adult (18–64 years) and elderly (≥ 65 years) subjects with insomnia as defined 
by [CONTACT_2681] -5 will be included  [see definition in S ection  1.1.1] , unless subject ’s insomnia  is 
associated with major comorbidities, especially comorbid neurological, affective or 
psychiatric disorders (e.g., severe or uncontrolled depression, anxiety or dementia)  that 
may interfere with the efficacy and safety in the trial.  
Elderly people exhibit a different sleep pattern t o younger adults [Ohayon 2004]  and the 
sensitivity of elderly and younger adults to the PD properties of a compound may therefore differ in the long term. Thus, randomization will be stratif ied by [CONTACT_223171][INVESTIGATOR_223130] a proportion of elderly subjects (i.e., 40% with age 
≥ 65 years) and to ensure balance of the treatment groups within strata is achieved. 
Concomitant pharmacological treatments for  insomnia or concomitant CNS -related 
medication s are not allowed in the study. This approach will favor optimizing the 
evaluation of the safety and efficacy profile of ACT -[ADDRESS_423014] .  
Criteria assessed at V isit 1 
1. Signed informed consent prior to any study- mandated  procedure. 
2. Male or female aged ≥ [ADDRESS_423015] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 49/[ADDRESS_423016] 2017 -004642 -20 
Doc No D- 18.160 
 
3. Insomnia disorder according to DSM- 5 criteria  as follows:  
3.1 The predominant complaint is dissatisfaction with sleep quantity or quality, associated with one (or more) of the following symptoms: 
• Difficulty initiating sleep.  
• Difficulty maintaining sleep, characterized by [CONTACT_341793]. 
• Early -morning awakening with inability to return to sleep.  
3.2 The sleep disturbance causes clinically significant distress or impairment in 
social, occupational, educational, academic, behavioral, or other important areas of functioning.  
3.3 The sleep difficulty occurs despi[INVESTIGATOR_42842]. 3.4 The insomnia is not better explained by [CONTACT_341794]- wake disorder (e.g., narcolepsy, a breathing -related 
sleep disorder, a circadian rhythm sleep -wake disorder, a parasomnia).  
3.5 The insomnia is not attributable to the physiological effects of a substance (e.g., a drug  of abuse, a medication). 
3.[ADDRESS_423017] 3 months prior to V isit 1: 
3.7.1 ≥ 30 min to fall asleep, and 3.7.2 Wake time during sleep ≥ [ADDRESS_423018] ≤ 6.5 h 
4. ISI
© score ≥ 15. 
5. Ability to communicate well with the investigator, to understand the study requirements and judged by [CONTACT_341795], place, 
time, and situation.  
Criteria assessed at V isit [ADDRESS_423019] 3 nights out of 7 nights on the sleep diary completed at home between V isit 2 and V isit 3: 
6.1 ≥ 30 min to fall asleep, and 6.2 Wake time during sleep ≥ [ADDRESS_423020] of ≤ 6.5 h 
7. Usual bedtime between 21:30 and 00:30, as reported on sleep diary completed between 
Visit 2 and Visit 3 . 
8. Regular time in bed between 6 and 9 h, as reported on sleep diary completed between 
Visit 2 and Visit 3 . 
9. Meeting all the following sleep parameters on the 2 PSG nights at Visit 3: 
9.1 Mean LPS ≥ 20 min (with none of the two nights < 15 min), and 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 50/[ADDRESS_423021] 2017 -004642 -20 
Doc No D- 18.160 
 
9.2 Mean WASO ≥ 30 min (with none of the two nights < 20 min), and 
9.[ADDRESS_423022] < 420 min 
Criterion assessed at V isit 1, Visit 2, and V isit 4 
10. For women of childbearing potential, the following is  required: 
• Negative serum pregnancy test (Visit 1). 
• Negative urine pregnancy test (V isit 2, Visit 4). 
• Agreement to use the contraception scheme as requ ired by [CONTACT_341796] [ADDRESS_423023] study treatment intake.  
4.4 Exclusion criteria 
Criteria assessed at V isit 1 
1. Body mass index (BMI) below 18.5 or above 40.0 kg/m2. 
2. Any lifetime history of sleep -related breathing disorder, including chronic obstructive 
pulmonary disease and sleep apnea.  
3. Cognitive behavioral therapy (CBT)  for any indication is allowed  only if the CBT  
started at least [ADDRESS_423024]  agrees to continue this CBT 
throughout the study. 
4. Self-reported usual daytime nappi[INVESTIGATOR_007] ≥ 1 hour per day, and ≥ 3 days per week. 
5. Acute or unstable psychiatric conditions (including but not restricted to anxiety 
disorder, major depression, bipolar disorder, schizophrenia, obsessive compulsive 
disorder or depression ) that are diagnosed by [CONTACT_341797] N europsychiatric 
Interview© (MIN I©) or that require pharmacological treatment for these disorders. 
N.B.: subjects with a history of major depressive disorder currently without any 
symptoms and not requi ring treatment are eligible.  
6. Mini Mental State Examination© (MMSE©) score < 25 in subjects ≥ 50 years.  
7. Shift work within 2 weeks prior to the screening visit, or planned shift work during the 
study.  
8. Travel across ≥ 3 time  zones within 2 weeks prior to the screening visit, or planned 
travel across ≥ [ADDRESS_423025] ’s safety or interfere 
with the study assessments.  
10. Treatment with CNS -active drugs prohibited by [CONTACT_223176] 5 half -lives of the 
respective drug (or 2 weeks, whichever is longer) prior to V isit 1, including 
over-the- counter medication and herbal medicines.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 51/[ADDRESS_423026] 3 consecutive day s. 
12. Heavy tobacco use (at least one pack of cigarettes a day or inability to refrain from 
smoking during the night).  
13. Caffeine consumption ≥ [ADDRESS_423027]  1 week prior to 
Visit 2.  
17. Not able or willing to stop consumption of grapefruit, Seville (bitter) oranges or juices from those fruits within at least  1 week prior to Visit 2.  
Criteria assessed at PSG visit between Visit 1 and Visit 2  
18. Periodic limb movement disorder with arousal index (PLMAI) ≥ 15/h (assessed on the 
1
st PSG night), restless legs syndrome, circadian rhythm disorder, REM behavior 
disorder, or narcolepsy.  
19. Apnea/hypopnea index (AHI) ≥ 15/h according to American Academy of Sleep Medicine criteria or event associated w ith blood oxygen saturation level by [CONTACT_3347] (SpO
2) < 80%, as assessed on the 1st PSG night. 
Criteria assessed at V isit [ADDRESS_423028] and/or ALT > 2 ×  ULN and/or direct bilirubin > 1.5 ×  ULN.  
21. Severe renal impairment: known or defined as estimate d creatinine clearance 
< 30 mL/min/1.73m2, according to the 4- variable Modification of Diet in Renal 
Disease formula.  
22. Hematology or biochemistry test results deviating from the normal range to a clinic ally 
relevant extent as per judgment of the investigator.  
23. Any of the following conditions related to ECG abnormalities : 
• A prolonged QT interval corrected with Bazett ’s formula (QTcB) or QT interval 
corrected with Fridericia ’s formula (QTcF) (greater than 450 ms). If QTcB or QTcF 
is greater than [ADDRESS_423029] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 52/[ADDRESS_423030] 2017 -004642 -20 
Doc No D- 18.160 
 
• A history of additional risk factors for torsade de pointes (e.g., heart failure, 
hypokalemia, family history of long QT syndrome). 
• ECG with clinically significant atrioventricular (AV) conduction disturbance (e.g., 
second - or third- degree AV block), sick sinus syndrome, bradycardia (resting pulse 
< 40 bpm), or accessory by[CONTACT_59585] ( e.g., Wolff-Parkinson- White).  
Criteri on assessed at V isit 1, Visit 2, Visit 3 and Visit 4  
24. Any of the following conditions related to suicidality:  
• Any suicidal ideation with intent, with or without a plan, at screening, i.e., 
answering “Yes” to questions 4 or 5 on the suicidal ideation section of the lifetime 
(Visit 1) and visit (V isit 2, Visit 3, Visit 4 ) version of the C- SSRS©. 
• History of suicide attempt on the suicidal behavioral section of the lifetime version of the C- SSRS
© (Visit 1).  
Criteria assessed at Visit 1, PSG visit between Visit 1 and Visit 2, Visit 2, Visit 3 and 
Visit 4 
25. For female subjects:  pregnant, lactating or planning to become pregnant during 
projected duration of the study. 
26. Positive urine drug test (for benzodiazepi[INVESTIGATOR_1651], barbiturates, cannabinoids, opi[INVESTIGATOR_858], amphetamines,  phencyclidine or cocaine) or presence of alcohol in exhaled breath as 
detected by [CONTACT_215202] . 
4.[ADDRESS_423031] one of the following criteria:  
• Previous bilateral salpi[INVESTIGATOR_1656], bilateral salpin go-oophorectomy or hysterectomy, 
• Postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause [ICH M3 definition]), 
• Premature ovarian failure (confirmed by a specialist), XY genotype, Turner 
syndrome, uterine agenesis, 
The reason for not being of childbearing potential will be recorded in the electronic Case 
Report Form (eCRF). 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 53/[ADDRESS_423032] 2017 -004642 -20 
Doc No D- 18.160 
 
4.5.2 Acceptable methods of contraception  
For women of childbearing potential [see definition in Section 4.5.1] , any of the following 
acceptable birth control methods are required: 
• Combined ( estrogen - and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation: 
– Oral 
– Intravaginal 
– Transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation: 
– Oral 
– Injectable  
– Implant able 
• Intrauterine device  
• Intrau terine hormone- releasing system  
• Vasectomized  male partner with documented post -vasectomy confirmation of the 
absence of sperm in the ejaculate.  
• Bilateral tubal occlusion (tubal occlusion / ligation at least 6 weeks prior to screening).  
• Sexual  abstinence from intercourse with a male partner only when this is in line with 
the preferred lifestyle of the subject and if locally accepted as a reliable method of 
contraception. 
Rhythm methods , the use of a female condom, cervical cap , diaphragm  or the partner ’s use 
of a condom are not considered acceptable methods of contraception for this study. 
The method of birth control used must be recorded in the hospi[INVESTIGATOR_1332].  To ensure compliance, the study personnel must remind women of childbearing potential 
at each visit to use the methods of contraception defined for this study. The reminders must be documented in the hospi[INVESTIGATOR_3853]. 
[ADDRESS_423033]-541468- matching placebo.  
5.1.1 Investigational treatment and matching placebo: Description and rationale  
ACT -[ADDRESS_423034] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 54/[ADDRESS_423035] -541468- matching placebo is supplied by [CONTACT_341798], formulated 
with the same inactive ingredients (excipi[INVESTIGATOR_840]) . 
5.1.[ADDRESS_423036] when taken at home and by [CONTACT_223178] ’s chart and the eCRF during the PSG nights. At Visit 2, the date of single -blind 
placebo treatment dispensing will also be recorded in the patient’ s chart and the eCRF.  
[IP_ADDRESS] Study treatment administration at site visits and at home  
During the PSG visits at the site, [ADDRESS_423037] meal and approximately 30  min (± 5 min) before lights off, in the evening of each 
PSG night. 
At home, the tablet will be taken at bedtime.  
[IP_ADDRESS] Missed doses 
If one or more doses have been missed, the next dose must be taken in the evening  of the 
following day. 5.1.[ADDRESS_423038] throughout the study. At Visit 1, after the ICF has been signed, the investigator/delegate will contact [CONTACT_341799] a subject number allocated to the subject.  
During the r un-in and run -out periods, subjects will receive single -blind placebo treatment. 
At Visit 2 and V isit 9, the investigator/delegate contacts the IRT system to assign the 
treatment wallet  number. 
On the day of randomization (V isit 4), after having verified t hat the subject meets all 
inclusion criteria and none of the exclusion criteria, the investigator/delegate contacts the 
IRT to randomize the subject. The IRT assigns the treatment wallet  number, which matches 
the treatment arm assigned per the randomization list.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 55/[ADDRESS_423039] 2017 -004642 -20 
Doc No D- 18.160 
 
Subjects will be randomized in a 1:1:[ADDRESS_423040] -541468, or placebo, 
respectively (i.e., approximately 300 subjects per arm). Treatment allocation will be stratified by [CONTACT_42889] 2 categories: <  65 and ≥ [ADDRESS_423041] Research Organization 
(CRO) and kept strictly confidential. 
5.1.4 Blinding  
[IP_ADDRESS] Run-in and run-out periods 
During run -in and run- out periods, placebo treatment will be administered in a single -blind 
fashion. The subjects will remain blinded to the study treatment until the end of the 
ID-078A303 extension study. Subjects must not be informed about the change in treatment 
at the end of run- in and at the beginning of run- out. The investigator and study personnel, 
the monitors, Idorsia personnel, and CROs involved in the conduct of the study will be 
unblinded to the treatment provided during the run-in/run-out periods.  [IP_ADDRESS] Double- blind treatment period 
From Randomization until EO DBT, the study will be performed in a DB fashion. The 
subjects, the investigator and site personnel, and the monitors w ill remain blinded to the 
study treatment until the end of the ID -078A303 extension study. Idorsia personnel 
responsible for clinical study supply distribution will monitor the depot stock levels in 
collaboration with the study team based on recruitment da ta and site activation. Site stocks 
will be maintained according to the settings in the IRT system.  
Until the time of unblinding for final data analysis, the randomization list is kept strictly confidential, and accessible only to the IRT vendor and sponsor authorized persons (e. g., 
Quality assurance, Systems and compliance personnel, Bioanalytical Laboratory group) the Independent Statistical Analysis Center ( ISAC ) and the IDMC, who are not involved 
in the conduct of the study. 
The investigational treatme nt and its matching placebo are indistinguishable, and all 
treatment wallets  will be packaged in the same way.  
To minimize the possibility of systematic unblinding, the results of PK data will not be 
communicated to the investigator and site study personne l, the subjects and Clinical 
Research Associates ( CRAs ) until the end of the ID -078A303 extension study. Results will 
be transferred by [CONTACT_341800] (for the PK data) to the sponsor and CRO personnel involved in the conduct of the study only after database lock . 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 56/[ADDRESS_423042] 2017 -004642 -20 
Doc No D- 18.160 
 
5.1.5 Unblinding  
[IP_ADDRESS] Unblinding for final analyses 
Randomization information will be made available for data analysis only after database 
lock, in accordance with Idorsia  Quality System (QS) documents. 
[IP_ADDRESS] Unblinding for IDMC review  
An ISAC, not otherwise involved in the design, conduct and analysis of the study, will have access to the randomization code in order to prepare unblinded reports for  IDMC 
review meetings during the course of the trial. The randomization code will be made available to the ISAC in accordance with the sponsor’s QS documents. 
[IP_ADDRESS] Unblinding for suspected unexpected serious adverse reaction s 
If a suspected unexpected serious adverse reaction (S[LOCATION_003]R) occurs for a subject 
participating in the study, Idorsia Global Drug Safety will request the unblinding of the treatment assignment. The treatment assignment will not be communicated to site personnel or to the Idorsia Clinical Trial Team. Unblinded S[LOCATION_003]R information will be provided to respective health authorities and IECs/IRBs only. S[LOCATION_003]Rs will be reported to investigators in a blinded fashion. 
[IP_ADDRESS] Emergency procedure for unblinding  
The investigator, study personnel and Idorsia personnel must remain blinded to the 
subject ’s treatment assignment. The identity of the study treatment may be revealed only 
if the subject experiences a medical event, the management of which would require knowledge of the blinded treatment assignment. In this case, the investigator can receive the unblinded treatment assignment through the IRT. In these situations, the decision to 
unblind resides solely with the investigator. Whenever possible, and if it does not interfere with (or does not delay) any decision in the best interest of the subject, t he investigator is 
invited to discuss the intended unblinding with Idorsia personnel. 
The occurrence of any unblinding during the study must be clearly justified and explained 
by [CONTACT_093]. In all cases, Idorsia personnel must be informed of the unblinding procedure as soon as possible before or after the unblinding. 
The circumstances leading to unblinding must be documented in the Investigator Site File 
(ISF) and eCRF . 
5.1.[ADDRESS_423043] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 57/[ADDRESS_423044] 2017 -004642 -20 
Doc No D- 18.160 
 
All study treatment supplies are to be used only in accordance with this protocol, and not for any other purpose. 
[IP_ADDRESS] Study treatment pack aging and labeling 
Study treatment (including placebo during run -in and run- out period)  is provided as tablets  
and supplied in wallets . All pack types  are childproof wallets  contain ing 35 tablets.  
Study treatment is labeled to comply with the applicable la ws and regulations of the 
countries in which the study sites are located. [IP_ADDRESS] Study treatment distribution and storage 
Study treatment supplies must be kept in an appropriate, secure area and stored according 
to the conditions specified on the label  (i.e., 8–25 °C) . Temperature measurement devices 
for study treatment storage area are required.  
[IP_ADDRESS] Study treatment dispensing  
The subjects will receive sufficient study treatment to cover the period up to the next scheduled visit. Subjects are asked to return al l used , partially used, and  unused study 
treatment wallets  at each vis it. If a treatment wallet is lost or damaged, a replacement wallet 
can be requested through the Treatment Replacement module of the IRT system. The 
protocol- mandated study  treatment dispensing procedures may not be altered without prior 
written approval from Idorsia . In exceptional circumstances (e.g., if the subject lost the 
study treatment between two visits, or if the subject is unable to return to the site due to a medic al emergency  / hospi[INVESTIGATOR_42853]), unscheduled dispensing and 
delivery of study treatment may occur outside of a scheduled visit. An accurate record of 
the date and amount of study treatment dispensed to each subject must be available for  
inspection at any time.  
[IP_ADDRESS] Study treatment return and destruction  
The protocol -mandated study treatment return procedures may not be altered without prior 
written approval from Idorsia . On an ongoing basis and/or on termination of the study, the 
CRA will collect used and unused treatment wallets , which will be sent to the warehouse, 
where Idorsia personnel or a deputy will check treatment reconciliation. In certain 
circumstances, used and unused study treatment containers may be destroyed at the site once study treatment accountability is finalized and has been checked by [CONTACT_341801], and written permission for destruction has been obtained from Idorsia. 
5.1.7 Study treatment accountability and compliance with study treatment  
[IP_ADDRESS] Study treatment acco untability  
The inventory of study treatment dispensed to and returned by [CONTACT_423] (i.e., study 
treatment accountability) must be performed by [CONTACT_341802] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 58/[ADDRESS_423045] the following information for each  study t reatment unit (i.e ., 
wallet ) dispensed to the subject: 
• Dispensed subject wallet  number. 
• Date and number of tablets dispensed. 
• Date and number of tablets returned. 
All study treatment supplies, including partially used or empty wallets must be retained at 
the site for review by [CONTACT_2689].  
If the subject forgets to bring the remaining study treatment to a study visit, he/she must be 
instructed to not take any tablets from the remaining study treatment wallet  and to return it 
at the next visit.  
[IP_ADDRESS] Study treatment compliance 
Study treatment compliance is based on study treatment accountability. Subjects also report their compliance in the eDiary every morning. Study treatment compliance for the Run-in period, the DB treatment period (Day 1 to EO DBT) and the Run- out period will be 
separately calculated for each of these periods by [CONTACT_341803]:  
Compliance = [(number of tablets dispensed – number of tablets returned) / total number 
of tablets that ne eds to be taken during the period
*] × 100 
* The period is defined as number of days during which study treatment should be taken as per actual visit 
dates . 
During the DB treatment period (Day 1 to EO DBT), compliance is expected to be at least 
70%. Compliance values below this will be considered as a protocol deviation which will be reported in the Clinical Trial Management System by [CONTACT_2689]. The investigator must discuss the non- compliance with the subject to clarify the reasons and to take appropriate 
actions to avoid re -occurrence. This discussion and its outcome must be documented in the 
source documents. 
5.1.[ADDRESS_423046] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 59/[ADDRESS_423047] for any reason, she/he must immediately inform the investigator.  
Interruptions of study treatment must be kept as short as possible.  
Study treat ment interruptions must be recorded in the e CRF.  
5.1.[ADDRESS_423048]’ s medical charts (e.g., AE, lack of efficacy) . 
A subject has the right to prematurely discontinue study treatment at any time , without any 
justification , by [CONTACT_42909] (i.e., premature withdrawal from the study  [see Section  8.2]). 
Although a subject is not obliged to give his/her reason for prematurely withdrawing from the treatment or the study, it is recommended that the investigator makes a reasonable effort to ascertain the reason(s), while fully respecting the subject ’s rights.  
The investigator must discontinue study treatment for a given subject if, on balance, he/she believes that continued administration would be contrary to the best interests of the subject.  
Study- specific criteria for discontinuation of st udy treatment are described in 
Section  5.1.10. 
A subject who prematurely discontinues study treatment is NOT  considered as withdrawn 
from the study and will be followed up until the planned EOS  (Day 115), provided that the 
subject ’s consent for this limited participation in the study has not been withdrawn. The 
subject is recommended to r eturn for safety assessments [see Table 1] within one week of 
his/her last DB study treatment intak e (N.B., next day residual assessments will only be 
performed if the subjects can be assessed within [ADDRESS_423049] DB study drug intake ). All 
subjects withdrawn from study treatment are encouraged to follow planned study procedures (e.g. , visits, sleep diary and questionnaire completion) until EOS. In this case, 
the run -out period (including Visit 9 and Visit 10)  will not be performed, and subjects will 
directly enter the follow -up period after Visit 8 (considered as EOT i n the event of  
premature discontinuation) . The phone call will be performed as planned 30  days (+ 7 days) 
later, at Visit [ADDRESS_423050] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 60/[ADDRESS_423051] to follow -up are also considered as withdrawn from the study. Withdrawal 
from the study and follow -up medical care of subjects withdrawn from the study are 
described in Sections  8.2 and 8.4,  respectively.  
5.1.10 Study -specific criteria for interruption / premature discontinuation of study 
treatment  
At each visit, if there are signs of any AEs, the investigator must evaluate whether continuing treatment at home is compatible with the  subject ’s lifestyle and does not affect 
the subject ’s safety. The investigator has the responsibility to decide whether it is safe for 
the subject to continue treatment in the study. 
If a subject becomes pregnant while on study drug, study drug must be permanently 
discontinued. The investigator must counsel the subject and discuss the risks of continuing with the pregnancy and the possible effects on the fetus. 
Female subjects participating in the study and wishing to become pregnant during the study 
must discontinue study drug and continue contraception for at least [ADDRESS_423052] dose of DB  treatment . 
5.2.2 Reporting of previous/concomitant therapy in the eCRF  
The use of all study -concomitant therapy (including contraceptives and traditional and 
alternative medicines, e.g., plant -, animal -, or mineral -based medicines) will be recorded 
in the eCRF. Previous therapy must be recorded in the eCRF if discontinued less than 
30 days prior to signing of the ICF. The generic name, start/end dates of administration (as 
well as whether it was ongoing at start of treatment and/or EOS), route, dose, and indication 
will be recorded in the eCRF.  
5.2.[ADDRESS_423053]. Given the shortage of certified sleep therapi[INVESTIGATOR_11437], access to CBT is limited, particularly in Europe [ Pi[INVESTIGATOR_42849]  2010, Schutte-Rodin 2008] . CBT  for any indication  is only 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 61/[ADDRESS_423054] ’s CBT or reason why CBT 
was not considered by [CONTACT_223185]. Initiation of CBT during the course of the study is not allowed. 
Therapi[INVESTIGATOR_164623] ’s well -being and not categorized a s 
prohibited concomitant medications can be used in this study. However, initiation of new 
medication is to be discouraged and concomitant medication will preferably not be changed during the study. Non- sedating antihistamines (cetirizine, loratadine, desloratadine, 
fexofenadine and  levocabastine) may be used a maximum of twice weekly for allergic 
symptoms. Inhaled or nasal corticosteroids are permitted.  
5.2.[ADDRESS_423055] rather be considered as non- eligible to the study, both due to their 
medical condition and due to their requirement for these therapi[INVESTIGATOR_014]. Several forbidden therapi[INVESTIGATOR_215177] (e.g ., cardiovascular disease, 
Parkinson’ s disease, stroke).  
The following concomitant therapi[INVESTIGATOR_215155]: 
• Treatment with another investigational drug until EOS.  
• Study-prohibited CNS -active medications from for 5 half -lives of the respective drug 
(but at least 2 weeks) prior to V isit 1 and until 24 hours after EOT  [see Appendix 3] . 
• Treatment with moderate or strong CYP3A4 inhibitors, or moderate or strong CYP3A4 
inducers until 24 hours after EOT  [see Appendix 3] .  
5.2.5 Forbidden concomitant diet and activities  
The following activities and diet are forbidden during the study: 
• Consumption of grapefruit, Seville (bitter) oranges or juices from those fruits from 
1 week prior to Visit 2 until 24  h after the end of run-out period. 
• Caffeine consumption ≥ 600 mg caffeine/day or consumption of any caffeine after 4 pm 
(after 2 pm on PSG nights) [see Appendix 2] . 
• Alcohol consumption [ see Appendix 1]  
− > 2 drinks a day 
− less than 3 hours before going to bed on non-PSG nights 
− within 24 hours prior to PSG night and during all PSG visits 
• Heavy tobacco use (at least one pack of cigarettes a day or inability to refrain from 
smoking during the night).  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 62/[ADDRESS_423056] 2017 -004642 -20 
Doc No D- 18.160 
 
• Driving or engaging in activities that require operating vehicles or dangerous 
machinery within [ADDRESS_423057] -541468 on 
objective and subjective endpoints.  
6.1 Primary efficacy endpoints 
The primary efficacy endpoints of this study are defined as: 
• the change from baseline to Month 1 in WASO (sleep maintenance) 
• the change from baseline to Month 3 in WASO 
• the change fro m baseline to Month 1 in LPS (sleep onset) 
• the change from baseline to Month 3 in LPS  
Baseline is defined as the mean of the 2 PSG nights at Visit 3 . Month 1 and Month 3 are 
defined as the mean of the 2 PSG nights at Visit 6 and Visit 8, respectively.  
LPS (min) is the time from start of recording to the beginning of the first continuous 
20 epochs (i.e., 10 min) scored as non- awake, i.e., epochs scored as either sleep stage 
1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep [SWS]) or REM, as determi ned 
by [CONTACT_63175].  
WASO is the time (min) spent awake after onset of persistent sleep until lights on, as 
determined by [CONTACT_63175] . 
6.2 Secondary endpoints  
The secondary efficacy endpoints of this study are defined as: 
• the change from baselinea to Month 1b in sTST  
• the change from baselinea to Month 3c in sTST  
• the change from baselinea to Month 1b in Insomnia Daytime Symptoms and Impacts 
Questionnaire (IDSIQ) sleepi[INVESTIGATOR_223115] 
• the change from baselinea to Month 3c in IDSIQ sleepi[INVESTIGATOR_223115]  
a Baseline is the mean value based on the screening sleep diary  / IDSIQ  entries performed 
at home in the [ADDRESS_423058] PSG at Visit 3.  
b ‘Month 1’ is the mean value based on the sleep diary  / IDSIQ  entries performed at home 
in the [ADDRESS_423059] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 63/[ADDRESS_423060] 2017 -004642 -20 
Doc No D- 18.160 
 
c ‘Month 3’ is the mean value based on the sleep diary  / IDSIQ  entries performed at home 
in the [ADDRESS_423061] PSG at Visit 8. 
6.3 Other efficacy endpoints  
• Change from baseline (mean  of the 2 PSG nights at Visit 3) to Month 1 (mean of the 
2 PSG nights at Visit 6) and Month 3 (mean of the 2 PSG nights at Visit 8) in TST . 
• Change from baselinea to Month 1b and Month 3c in subjective WASO (sWASO) . 
• Change from baselinea to Month 1b and Month 3c in subjective Latency to Sleep Onset 
(sLSO) . 
• Change from baselinea to Month 1b and Month 3c in IDSIQ scores (i.e., Total score; 
alert/cognition and mood domain scores). 
a Baseline is the mean value based on the screening sleep diary  / IDSIQ  entries performed 
at home in the [ADDRESS_423062] PSG at Visit 3.  
b ‘Month 1’ is the mean value based on the sleep diary / IDSIQ entries performed at home 
in the [ADDRESS_423063] PSG at Visit 6.  
c ‘Month 3’ is the mean value based on the sleep diary / IDSIQ entries performed at home 
in the [ADDRESS_423064] PSG at Visit 8. 
6.4 Exploratory endpoints 
For each variable, multiple aspects will be considered in the analysis, in particular changes 
from baseline at different time points.  
• WASO over time (by [CONTACT_215259]) on each PSG night.  
• Change from baseline (Visit 3) to Month 1 and Month 3 in SQ. SQ is the sleep quality 
as determined by [CONTACT_215260] (mm) in the morning. 
• Change from baseline (Visit 3) to Month [ADDRESS_423065] in each 
sleep stage (S1, S2, SWS and REM).  
• Change from baseline (Visit 3) to Month [ADDRESS_423066] in each sleep stage (S1, S2, SWS, and REM) over the whole night, and for each quarter of the night.  
• Change from baseline (Visit 3) to Month 1 and Month 3 in mean numbers of shifts from S2, SWS or REM to S1 or a wake.  
• Change from baseline (Visit 3) to Month 1 and Month 3 in ISI
© scores.  
• Change from baseline (Visit 3) to Month 1 and Month 3 in mean number of awakenings (defined as the number of awakenings between first epoch and last epoch not scored 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 64/[ADDRESS_423067] 2017 -004642 -20 
Doc No D- 18.160 
 
wake) as measu red by [CONTACT_63175] (will be summarized for the whole night, for each quarter 
of the night, and for each hour of the night). 
• Change from baseline (Visit 3) to Month 1 and Month 3 in mean number of 
self-reported awakenings.  
• Change from baseline (Visit 3) to Month 1 and Month 3 in sWASO. 
• Change from baseline (Visit 3) to Month 1 and Month 3 in Sleep Efficiency (defined 
as 100 ×  ([TST / time in bed]).  
• Change from baseline (Visit 1) to Month 1 and Month 3 in Patient Global Assessment 
of Disease Severity (PGA -S) scores  (daytime symptoms) . 
• Change from baseline (Visit 3) to Month 1 and Month 3 in Patient Global Impression 
of Change (PGI- C) scores  (daytime symptoms) . 
• Change from baseline (Visit 3) to Month 1 and Month 3 in PGI-C scores (night -time 
symptoms).  
• Change from baseline (Visit 3) to Month 1 and Month 3 in Patient Global Impression of Severity (PGI -S) scores  (night- time symptoms) . 
6.5 Safety endpoints  
In addition to the standardized collection of AEs, safety data specific to insomnia and its treatment will be assessed  as follows:  
• Withdrawal effects (physical dependence) upon treatment discontinuation will be 
assessed based on the changes from last assessment on DB treatment (Visit  8, 
2
nd morning) to run- out period in the BWSQ total score (Visit 9 and Visit 10), the 
occurrence of relevant AEs and marked ECG abnormalities.  
• Rebound insomnia will be assessed based on objective sleep parameters (WASO, LPS 
and TST) at Visit 9 as compared to Visit 3. It will also be assessed using subjective 
sleep parameters (sWASO, sLSO and sTST) from run -out period as compared to 
baseline.  
• Next -day residual effect will be assessed based on changes from baseline (Visit 3) to 
Month 1 and Month 3 in: 
− Coding sub- test© 
− SDS© 
− Scores on the VAS (mm) 
• SAEs up to 30 days after DB study treatment discontinuation or until enrollment into 
the extension study. 
• TEAEs up to [ADDRESS_423068] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 65/[ADDRESS_423069] 2017 -004642 -20 
Doc No D- 18.160 
 
• AEs leading to premature discontinuation of the DB study treatment.  
• AEs of special inte rest after adjudication by [CONTACT_42910]:  
− narcolepsy -like symptoms (i.e. , EDS, cataplexy and complex sleep behavior 
events incl uding hallucinations/sleep paralysis)  
− suicide/self -injury  
• Change from baseline (Visit 3) to Month 1 (Visit 6) and Month 3 (Visit 8) in vi tal signs 
(mean of the 2 PSG nights in systolic and diastolic blood pressure [BP] and pulse rate).  
• Change from baseline (Visit 1 ) to Month 3 (Visit 8) in body weight. 
• Marked ECG abnormalities on DB study treatment.  
• Change from baseline (Visit 3) to Month 3  (Visit 8) and the end of the run- out period 
(Visit 10) in ECG parameters.  
• Marked laboratory abnormalities on DB study treatment.  
• Change from baseline (Visit 3) to Month 1 (Visit 6) and Month 3 (Visit 8) in laboratory 
parameters.  
• Occurrence of suicidal ideation and/or behavior on DB study treatment based on 
C-SSRS©. 
6.[ADDRESS_423070] -541468 plasma concentrations 9–[ADDRESS_423071] -dose (morning after the second PSG night 
at Visit 6 and Visit 8) or in the event of excessive sleepi[INVESTIGATOR_223133] ’s 
opi[INVESTIGATOR_1649]. 
6.[ADDRESS_423072] section of the PAUSe 
questionnaire will be used to derive the following endpoints: 
• Partial value of each treatment outcome  at Visit 4 and V isit 8. 
• Partial value function and weights for each treatment outcome at V isit 4 and V isit 8. 
• Total value score for each treatment at V isit 4 and V isit 8. 
• Change in  total value score for each treatment from V isit 4 to V isit 8.  
• Probability that patients would  prefer a treatment at V isit 4 and V isit 8. 
• Change in probability that patients would prefer a treatment from V isit [ADDRESS_423073] be seen on the designated day and within a ±  [ADDRESS_423074] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 66/[ADDRESS_423075] 2017 -004642 -20 
Doc No D- 18.160 
 
days visit  window in comparison with randomization (Visit 4). A follow -up safety 
telephone call must be performed 30 days (+ 7 days) after last DB study treatment intake if the subject is not enrolled in the ID-078A303 extension study. 
7.1.1 Screening  
At Visit 1 subjects will discuss and sign the ICF, and will undergo initial eligibility 
assessments. The date on which the ICF is signed corresponds to the date of the screening 
visit (Visit 1).  
It is the responsibility of the investigator/delegate (the latter may or may not be a physician  
according to local legal requirements, in the EU it must be a physician) to obtain written informed consent from each subject participating in this study after adequate face -to-face 
explanation of the objectives, methods, and potential risks of the study. The subjects who 
agree to participate in the study and the investigator/delegate must sign the ICF prior to performing any study -related  assessment or procedure.  
Subjects who are in the screening phase when the enrollment target has been met may still be randomized. 
It is not permitted to re -screen subjects . 
7.1.2 Unscheduled visits  
Unscheduled visits may be performed at any time during the study. Depending on the 
reason for the unscheduled visit (e.g., AE), appropriate assessments will be performed based on the judgment of the investigator. Results of ECG s and  laboratory assessments, 
and changes in concomitant treatment will be recorded in the eCRF. After an unscheduled visit, the regular scheduled study visits must continue according to the planned visit and  
assessment schedule [Table 1]. 
 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 67/[ADDRESS_423076] 2017 -004642 -20 
Doc No D- 18.160 
 
Table 1 Visit and assessment schedule  
 SCREENING PHASE (20 –31 days)  TREATMENT PHASE (82 –86 days)  FU PHASE (30 –37 days)  
 Screening period  
(7–18 days)  Run-in period  
(13–24 days)  Double -blind treatment (84 days ± 2 days13) Run-out period  
(7 days + 2 days)  FU period  
(23 days + 
7 days)17 
Visit  1  2 3 416 5 
(phone call)  6 7 8 9 10 11 
(phone call)  
Target Study Days     1st night  2nd night [ADDRESS_423077] night 13 
27/28 2nd night 
28/[ADDRESS_423078] night 13 
83/84 2nd night 
84/85 85/86 92 
(+ 2 days)  115 
(+ 7 days)  
Evening(PM) /  
Morning (AM )  
PM AM  PM AM PM AM   PM AM PM AM  
PM AM PM AM PM AM   
Informed consent  X                       
Inclusion and exclusion 
criteria  X X X X X X X X X               
Demographics  X                       
Medical history  X                      X 
Concomitant therapy  X X X X X X X X X X X X X X X X X X X6 X X X X 
Physical examination, body 
weight and height  [ADDRESS_423079]  X X  X X  X  X  X  X   X  X  X  X  
PK sampling               X     X     
PSG   X4  X X   X X  X X X   
ISI© X       X      X     X6     
IDSIQ                         
Sleep diary (incl. VAS)2                        
Neurological exam8   X   X  X    X  X   X  X  X   
C-SSRS© [ADDRESS_423080]© 7      X  X    X  X   X  X15  X   
ESS© X   X    X      X     X   X  
SDS© 7      X  X    X  X   X  X6  X   
BWSQ7        X      X     X6  X X  
MINI© X                       
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 68/[ADDRESS_423081] 2017 -004642 -20 
Doc No D- 18.160 
 
 SCREENING PHASE (20 –31 days)  TREATMENT PHASE (82 –86 days)  FU PHASE (30 –37 days)  
 Screening period  
(7–18 days)  Run-in period  
(13–24 days)  Double -blind treatment (84 days ± 2 days13) Run-out period  
(7 days + 2 days)  FU period  
(23 days + 
7 days)17 
Visit  1  2 3 416 5 
(phone call)  6 7 8 9 10 11 
(phone call)  
Target Study Days     1st night  2nd night [ADDRESS_423082] night 13 
27/28 2nd night 
28/[ADDRESS_423083] night 13 
83/84 2nd night 
84/85 85/86 92 
(+ 2 days)  115 
(+ 7 days)  
Evening(PM) /  
Morning (AM )  
PM AM  PM AM PM AM   PM AM PM AM  
PM AM PM AM PM AM   
MMSE©[ADDRESS_423084] IRT  X   X     X  X    X     X    
Randomization12         X               
Dispense IMP wallet(s)     X     X  X    X     X    
Study drug intake3                        
SAEs and AEs [ADDRESS_423085] PSG can be performed any nights between V1 and V2. It 
includes assessment of AHI, PLMAI, SpO 2. 5. SAE and  AE reporting and follow -up: all SAEs and AEs from signed ICF up to EOS . 6. In the event of permanent study treatment discontinuation, safety 
assessments of V [ADDRESS_423086]  remain s in the study, he or she will  perform study visits and assessments as planned until EOS 
(Day 115), without the run- out period ( including Visit 9 and Visit 10).  7. Approximately 30 to 60 minutes after PSG lights on. 8. Performed approximately 1 hour after lights on. 9. Height only at V1. 10. For 
elderly subjects only. 11. PGA-S , PGI -S and PGI -C (daytime symptoms and night -time symptoms questionnaires) will be completed at home once a week between V4 and EO DBT. 12. Randomization will 
take place after all the V4 assessments have been performed and provided the subject fulfills all the eligibility criteria. 13. A time window of ± 2 days is allowed at each visit vs randomization visit (V4).  
14. Patient preferences sub-study (PA USe) available for sites in [LOCATION_013] and in the [LOCATION_003] only.  15. In the event of permanent study treatment discontinuation, next day residual assessment of V [ADDRESS_423087] DB study drug intake.  16. Three working days are required between V3 and V4 to obtain eligibility confirmation regarding objective sleep parameters. 
17. If Run -out period exceeded by 2 days, then the follow -up period can only be exceeded by a maximum of 5 days.  
 
AE = adverse event; AHI = apnea/hypopnea index; BWSQ = Benzodiazepi[INVESTIGATOR_42831]; C -SSRS© = Columbia Suicide Severity Rating Scale; ECG  = electrocardiogram; EO DBT = 
End-of-Double -Blind -Treatment; EOS = End -of-Study ; ESS© = Epworth Sleepi[INVESTIGATOR_7110]©; FU = Follow -up; ICF = Informed Consent Form; IDSIQ = Insomnia Daytime Symptoms and Impacts Ques tionnaire; 
IMP = Investigational Medicinal Product; IRT = Interactive Response Technology; ISI© = Insomnia Severity Index©; MINI© = Mini International Neuropsychiatric Interview©; MMSE© = Mini Mental State 
Examination©; PAUSe = PAtient Preferences StUdy in  InSomnia; PGA-S = Patient Global Assessment of Disease Severity; PGI -C = Patient Global Impression of Change  (daytime symptoms and night -time 
symptoms) ; PGI-S = Patient Global Impression of Severity; PK = pharmacokinetic; PLMAI = periodic limb movement wi th arousal index; PSG = polysomnography; SAE = serious adverse event; SDS© = 
Sheehan Disability Scale©; SpO 2 = oxygen saturation by [CONTACT_406]; V = Visit; VAS = visual analog scale(s).  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 69/[ADDRESS_423088] 2017 -004642 -20 
Doc No D- 18.160 
 
 7.2 Study assessments 
The mandatory study assessments are listed in  Table 1.  
All study assessments are performed by [CONTACT_9260] (medical, nursing, or 
specialist technical personnel) , and are recorded in the medical history and eCRF  unless 
otherwise specified. Study assessments performed during unscheduled visits will also be recorded in the eCRF.  
The f ollowing order of assessments is recommended:  
• In the evening before a PSG night: 
– Urine drug screen and alcohol test 
– IDSIQ  
– Evening questionnaire in sleep diary (including VAS) 
– PGA- S daytime symptoms (in the first evening at Visits 3, 6 and 8) 
– PGI-C daytime symptoms (in the first evening at Visits 3, 6 and 8) 
– Recording of concomitant medications 
– AEs and SAEs  
– Study drug intake (30 minutes before lights off) 
• In the morning after a PSG night (subject fasted) : 
– Blood samples (hematology and blood chemistry, only second morning at 
Visits  3, 6 and 8; PK, only second morning at Visits 6 and 8.  
• In the morning after a PSG night and after completion of normal morning routine (e.g., using the bathroom, eating breakfast): 
– Vital signs  
– C-SSRS
© (only second morning at Visits 3, 6 and 8) 
– Coding sub- test© 
– ISI© (only second morning at Visits 3, 6 and 8) 
– ESS© 
– SDS© 
– BWSQ (only second morning at Visits 3, 6, 8 and 9) 
– Morning ques tionnaire in sleep diary (including VAS)  
– PGI-S night- time symptoms (in the first morning at Visits 3, 6 and 8) 
– PGI-C night- time symptoms (in the first morning at Visits 3, 6 and 8) 
– Recording of concomitant medications 
– AEs and SAEs  
– Neurological examination  
– 12-lead ECG ( only second morning at Visits 3and 8) 
– Patient preferences questionnaire PAUSe (only second morning at Visit 8) 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 70/[ADDRESS_423089] 2017 -004642 -20 
Doc No D- 18.160 
 
 The following assessments will be analyzed by [CONTACT_42911] (results will be 
transferred to the Idorsia database and to the investigators):  
• Laboratory parameters  
• ECG parameters  
• PSG recordings  
• Questionnaires completed using a hand-held device (listed below). 
If the Principal Investigator (PI) delegates any study procedure/assessment for a subject, to an external facility, he/she must inform Idorsia to whom these tasks are delegated. The set -
up and oversight must be agreed upon with Idorsia. The supervision of any external facilities remains the responsibility of the PI.  
Calibration certificates / evidence of equipment maintenance for the below -listed 
equipment used to perform study assessments must be available prior to the screening of the first subject. Calibration certificates of other equipment must be available as per local requirements:  
• Temperature measurement devices for study treatment and sample storage area.  
• Polysomnographic device. 
Use of hand- held and tablet devices  
Subjects will be required to complete the following questionnaires on a hand- held device:  
Epworth Sleepi[INVESTIGATOR_7110]© (ESS©), ISI©, SDS©, BWSQ, IDSIQ, PGA-S daytime 
symptoms , PGI -C daytime and night -time symptoms , PGI -S night- time symptoms , sleep 
diary  (including VAS). 
Subjects will be required to complete the following questionnaires on a tablet at site:  
Patient preferences questionnaire (PAUSe).  
Investigato rs, delegated physicians, specialist nurses or nurse practitioners  trained 
according to local requirements and local clinical practi ce will be required to complete the 
following questionnaires on a tablet at the site: C -SSRS©, MMSE©. 
Sites will be properly  trained on the accurate use of the hand -held and tablet devices by [CONTACT_341804]. Data collected from the hand- held devices will 
be electronically transferred to Idorsia by [CONTACT_2024].  
For further details refer to the tablet and hand- held devices manual .  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 71/[ADDRESS_423090] 2017 -004642 -20 
Doc No D- 18.160 
 
 7.2.1 Demographics 
Demographic data to be coll ected in the eCRF for  all subjects include: a ge, sex, race and 
ethnicity. Relevant medical history  / current medical conditions (e.g., chronic and ongoing 
acute conditions, serious past conditions) present before signing informed consent will be 
recorded on the medical history page. Where possible, diagnoses and not symptoms will be recorded.  
Characteristics  of insomnia will be captured on a specific Diagnosis e CRF page .  
Subject ’s information regarding CBT will be captured on a specific Medica l History eCRF 
page.  
For subjects who failed screening, the following data will be collected  in the eCRF if 
available:  
• Demographics (i.e., age, sex, race and ethnicity)  
• Informed c onsent date  
• Reason for screening failure  
• AEs. 
7.2.2 Efficacy assessments  
[IP_ADDRESS] Polysomnography 
PSG data will be used to assess objective sleep parameters (WASO  and LPS) as well as 
data on sleep architecture (sleep stages).  
PSG recordings must be performed by [CONTACT_341805], processing, scoring, archiving, and transfer of digital PSG data (provided by [CONTACT_223187]). The quality of PSG recordings is monitored and quality -controlled on an 
ongoing basis. Technologists must be able to follow the procedures in this manual in order to produc e technically acceptable tracings. Technologists are not required to be registered 
PSG technologists. Technologists must receive study -specific training prior to their 
participation in the study. Documentation of technologists ’ prior experience and trainin g, 
and study -specific training will be maintained at each clinical trial site. The sites and 
scorers that participate in this study must be certified by [CONTACT_2024]. The center conditions must allow an undisturbed environment and PSG recordings must be conduct ed in a sleep 
laboratory environment that meets the guidelines for sleep disorder centers [aasmnet.org ]. 
During the Screening period, a PSG night will be performed if the subject  meets all 
inclusion criteria and none of the exclusion criteria checked so far, and assesses AHI, PLMAI, and SpO
2. At Visit 3, the first PSG recording starts (lights off) within ± [ADDRESS_423091] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 72/[ADDRESS_423092] 2017 -004642 -20 
Doc No D- 18.160 
 
 usual bedtime (determined by [CONTACT_341806] 2 and Visit 3); this time is then 
considered as the habitual bedtime and held constant (±  15 min) throughout the study. 
Study medication is administered 30 min (±  5 min) before the recording starts. The PSG 
recording is stopped after [ADDRESS_423093] been recorded. 
PSGs will be performed as per the visit and assessment schedule [Table 1].  
During the PSG recording, the subject is requested to stay in bed and remains connected to the recording equipment. However, if the subject needs to go to the bathroom, he/she may do so and will be disconnected for this short time from the recording device. Alternatively, urine flasks or bedpans may be provided. The subject must be re -connected as quickly as 
possible. The time during which the subject is disconnected will be scored as time awake. 
The subject is not permitted to perform any cognitive activity (such as reading, listening to radio, etc.), and is recommended not to have a watch or access to any clock. The lights remain switched off until the [ADDRESS_423094] PSG and at Visit 3 according to site scoring (more than 10% deviation from protocol range) are not required to be sent for central scoring. If anything prevents any PSG night being scored, the center must contact [CONTACT_215245]. After Visit 3, the CRO will score the PSG data obtained at the first PSG and at Visit 3 immediately upon receipt and the center will receive the complete Eligibility Assessment (AHI, PLMAI, and the presence of any apnea/hypopnea or event associated with SpO
2 < 80% as assessed at Visit 1, and WASO, 
LPS and TST as assessed at Visit 3) within 3 business days following file receipt by [CONTACT_2024]. These PSG data are evaluated and scored centrally by [CONTACT_215242] (expert 
from central reading CRO, not otherwise involved in the study). Based on this information, the investigator assesses the subject ’s potential eligibility.  
Results of all PSG nights (1
st PSG, Visit 3, Visit 6, Visit 8, and Visit 9) for the randomized 
subjects are sent to Idorsia from the central scoring CRO. The following sleep variables assessed by [CONTACT_223188] : WASO, LPS, TST, sleep stages S1 (also 
called N1), S2 (N2), SWS (N3), REM (R), and Wake time during sleep (W). The definitions of the sleep variables are given in the scoring procedures of the central scoring CRO manual.  
The sponsor reserves the right to  request the sites to provide PSG data from th e [ADDRESS_423095] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 73/[ADDRESS_423096] 2017 -004642 -20 
Doc No D- 18.160 
 
 For more detailed information, refer to the investigator site operations manual for the 
acquisition, processing, scoring, archiving, and transfer of digital PSG data (provided by [CONTACT_223189]) . 
[IP_ADDRESS] Sleep diary 
The sleep diary (also called eDiary) will be uploaded into an electronic hand- held device 
and given to the subjects at Visit 1. Sleep diaries will be available in the subject ’s language, 
and must be completed daily from V isit 1 at screening and until V isit 10. 
The self -administered sleep diary includes a morning and evening questionnaire, and VAS.  
For further information about the set -up and the use of  the sleep diary on the hand-held 
device, refer to the investigator site electronic Clinical Outcome Assessment study information guide (provided by [CONTACT_51070]).  
[IP_ADDRESS].[ADDRESS_423097] information on self -reported sleep characteristics (sleep induction 
and maintenance), habitual nappi[INVESTIGATOR_007], bedtime, and timing of study treatment intake.  The subject ’s answer to the sleep diary question “What time did you get into bed? ” is 
expected to be in the time window of 21:30 to 00:[ADDRESS_423098] 50% of the nights between 
Visit 2 and Visit 3. The median of the values falling into the time window of 21:30 to 00:[ADDRESS_423099] ’s 
regular time in bed (i.e., time calculated from “What time did you get into bed? ” until 
“What time did you get out of bed for the day? ”) is expected to be in the time window of 
[ADDRESS_423100] 50% of the nights between Visit 2 and Visit 3. 
For further details, see Appendix 8.  
[IP_ADDRESS].[ADDRESS_423101] s information on quality of sleep, depth of sleep, morning sleepi[INVESTIGATOR_008], 
daytime alertness, and daytime ability to function by [CONTACT_42916] a mark on a visual analog scale.  
Self-reported quality of sleep, depth of sl eep and morning sleepi[INVESTIGATOR_42859]. Self -reported daytime alertness and daytime ability to function are assessed in 
the evening.  
For further details, see Appendix 8.  
[IP_ADDRESS] Insomnia Severity Index
© 
The ISI© assesses the severity of a patient ’s insomnia by [CONTACT_42917] -related interference with daytime 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 74/[ADDRESS_423102] 2017 -004642 -20 
Doc No D- 18.160 
 
 functioning [see Appendix 5] . The assessment is on a 5 -point scale (0 –4), where the 
composite score is obtained by [CONTACT_10621] [ADDRESS_423103] ’s 
perception of his or her insomnia. A score of 15–21 indicates a moderate level of insomnia 
and a score of 22–28 indicates severe insomnia. An ISI© total score < [ADDRESS_423104] ’s subjectively -rated insomnia symptoms, daytime impairment, and quality of life 
have improve d to the minimal- to-none range [Morin  1993, Scharf  2007] . The ISI© will be 
completed by [CONTACT_42918]- held device at V isit 1, V isit 3, Visit 6, and V isit 8.  
[IP_ADDRESS] Patient Global Assessment of Disease Severity  (daytime symptoms)  
The PGA -S (daytime symptoms) is a question concerning the overall severity of daytime 
symptoms (e.g., sleepi[INVESTIGATOR_008]) and impacts (e.g., effort to perform daily activities) that the subject may have experienced due to his/her insomnia over the [ADDRESS_423105] evening , 
Visit 10, and weekly in the evening at home from Visit 4 until EO DBT.  
For further details, see Appendix 9.  
[IP_ADDRESS] Patient Global Impression of Change (d aytime symptoms ) 
The PGI -C (daytime symptoms ) is a question concerning the change in overall severity of 
daytime symptoms (e.g., sleepi[INVESTIGATOR_008]) and impacts (e.g., effort to perform daily activities) that the subject may have experienced due to his/her insomnia over the 7 days preceding the PGI -C daytime symptoms compared to the week before he/she started treatment. The 
PGI-C daytime symptoms is a self -administered question on the hand -held device and is to 
be comple ted at Visit [ADDRESS_423106] evening, Visit 10, and 
weekly in the evening at home  from Visit 4 until EO DBT. 
For further details, see Appendix 9.  
[IP_ADDRESS] Patient Global Impression of Change (n ight-time symptoms ) 
The PGI -C (night- time symptoms ) is a question concerning the change in the subject ’s 
insomnia symptoms at night (e.g. , trouble falling asleep, total time asleep, or number of 
times they wake up) over the past week (7 nights) preceding the PGI -C night- time 
symptoms compared to the week before the subject  started treatment. The PGI -C 
night- time symptoms is a self -administered question on the hand- held device and is to be 
completed at Visit [ADDRESS_423107] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 75/[ADDRESS_423108] 2017 -004642 -20 
Doc No D- 18.160 
 
 [IP_ADDRESS] Patient Global Impression  of Severity (night -time symptoms)  
The PGI -S is a question concerning the overall se verity of the subject’s night- time 
symptoms (e.g., trouble falling asleep, total time asleep, or number of times they wake up)  
that the subject may have experienced due to his/her insomnia over the past week (7  nights) 
preceding the PGI -S. It is a self-administered question programmed on the hand- held 
device and is to be completed at Visit 1, Visit 2, Visit [ADDRESS_423109] morning , Visit 10 and weekly in the morning at home  from Visit 4 until EODBT.  
For further detail s, please see Appendix 10. 
[IP_ADDRESS] Insomnia Daytime Symptoms and Impacts Questionnaire 
The IDSIQ is programmed on the electronic hand -held device in the subject ’s language, 
and must be completed every day in the evening before the evening sleep diary by [CONTACT_341807] (Visit 1) until EOT  
(Visit 10).  
The IDSIQ  is structured in 3 domains (i.e., alertness/cognition; negative mood; 
tiredness/sleepi[INVESTIGATOR_008]) and contains overall 1 4 items, each based on an 11 -point numeric 
rating scale. This tool is based on an existing instrument, the D aytime Insomnia Symptom 
Scale [Buysse  2007] . The psychometric validation of the IDSIQ instrument was performed 
in study ID-078A203. 
For further details, see Appendix 11.  
7.2.3 Safety assessments  
The definitions, reporting and follow -up of AEs, SAEs and pregnancies are described in 
Section  9. 
[IP_ADDRESS] Weight and height 
Height will be measured at Screening only (V isit 1) and recorded in the eCRF. 
Body weight will be measured at Screening (V isit 1) and EO DBT visit (V isit 8), and 
recorded in the eCRF. BMI will be calculated at V isit 1 according to the BMI formula 
(weight in kg/m2) and displayed automatically upon entry of weight and height in the 
eCRF .  
[IP_ADDRESS] Physical exa mination  
Physical examination will be performed at Screening (V isit 1) and EODBT visit (Visit 8) 
according to site standard medical practice for subjects with insomnia disorders.  
Other exams will be performed if indicated, based on medical history and/or symptoms.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 76/[ADDRESS_423110] be recorded on the Medical 
History eCRF form. Clinically significant physical examination findings made after signing of informed consent  that meet the definition of an AE [Section  9.1.1]  must be 
recorded on the AE form of the eCRF. 
[IP_ADDRESS] Vital signs  
Systolic and diastolic BP and  pulse rate will be measured non- invasively at each study visit 
from Screening (V isit 1) to EOT  (Visit 10).  
Vital sign s measurements will be collected in the eCRF.  
[IP_ADDRESS] Coding s ub-test
© 
The Coding sub- test©, formerly known as Digit Symbol Substitution Test, is a measure of 
attention, perceptual speed, motor speed, visual scanning and memory.  On a sheet of paper, the subject is given 120 seconds to complete as many substitutions as 
possible, entering a symbol in numbered boxes according to a key shown on the top of the sheet (9 symbols).  
The Coding sub- test
© is performed at Visit 3, Visit 6, Visit [ADDRESS_423111]© score and collected in the 
eCRF . 
For further details, see Appendix 4.  
[IP_ADDRESS] Sheehan Disability Scale© 
The SDS© consists of 3 questions on impairment of work, social life, and family life  / home 
responsibili ties [see Appendix 6; Sheehan 1996] . The SDS© is a self -administered 
questionnaire on the hand-held device performed at Visit 3, Visit 6, Visit 8 and Visit 9.  
[IP_ADDRESS] Columbia Suicide Severity Rating Scale© 
The C -SSRS© is an instrument  that reports the presence and severity of both suicidal 
ideation and behaviors [Posner 2007]. Suicidal ideation is classified on a 5 -item scale:  
1. Wish to be dead  
2. Non-specific active suicidal thoughts  
3. Active suicidal ideation with any methods (not plan) without intent to act 
4. Active suicidal ideation with some intent to act, without specific plan  
5. Active suicidal ideation with specific plan and intent 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 77/[ADDRESS_423112] 2017 -004642 -20 
Doc No D- 18.160 
 
 The C -SSRS© also captures information about the intensity of ideation, specifically the 
frequency, duration, controllability, deterrents, and reasons for the most severe types of 
ideation. In addition, the C -SSRS© captures information using yes/no question and answers 
on suicidal behaviors, specifically actual, interrupted, and aborted attempts; preparatory acts or behaviors; and if suicidal behaviors were present during the assessment period. More than one classif ication can be selected provided they represent separate epi[INVESTIGATOR_1841]. For 
actual attempts only, the actual or potential lethality is classified for the initial, most lethal, and most recent attempts. The C -SSRS
© will be completed at all study visits except Visit 
5 and Visit 11 (i.e., telephone calls). At Visit 1 (Screening) the C -SSRS© will be completed 
for the subject lifetime history of suicidal ideation and behaviors. At all other visits, the C -
SSRS© will be completed for ideation and behaviors since the previous visit.  
At each visit, the investigator , a delegated physician, a specialist nurse or a nurse 
practitioner, trained according to local requirements and local clinical practice will 
complete this questionnaire with the subject on a tablet  and assess the findings.  
[IP_ADDRESS] Benzodiazepi[INVESTIGATOR_341780] [see Appendix 7 ; Tyrer  1990] . The questionnaire 
consists of 20 items. The symptoms will be rated from  0 (No), 1 (Yes -moderate) to 
2 (Yes -severe). The questionnaire will be self -administered using the hand- held device  at 
Visit 3, Visit 6, Visit 8, Visit 9 and Visit 10. 
[IP_ADDRESS] Mini International Neuropsychiatric Interview© 
The MINI© is a psychiatric examination [Sheehan  1999]  and will identify subjects with 
exclusionary psychiatric conditions. The MINI© will be administered at Screening (Visit  1) 
by [CONTACT_093], a delegated physician, a specialist nurse or a nurse practitioner, trained 
according to local requirements and local clinical practice. The MINI© Version  7.0.2 will 
be administered on paper  to ascertain the psychiatric diagnoses , and any clinically relevant 
psychiatric conditions will be reported in the eCRF. 
[IP_ADDRESS] Mini Mental State Examination© 
The MMSE© is a simplified, scored form of the cognitive mental status examination  [see 
Appendix 13; Folstein  1975] . The MMSE© assesses orientation, attention, immediate and 
short- term recall, language, and the ability to follow simple verbal and written commands. 
The MMSE© will be administered at Screening (Visit 1) for  subjects  ≥ [ADDRESS_423113] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 78/[ADDRESS_423114] 2017 -004642 -20 
Doc No D- 18.160 
 
 [IP_ADDRESS] Neurological examinations 
At 1st PSG night , Visit 3, Visit 6, Visit 8, and Visit 9, a set of examinations must be 
performed approximately 1 hour after lights on [see Section 7.2]. The neurological 
examinations will be done by [CONTACT_20616] r, a delegated physician, a specialist nurse or 
a nurse practitioner, trained according to local requirements and local clinical practice. The 
following examinations will be performed to detect a possible next-day residual effect : 
• Gait 
• Tandem walking  
• Rombe rg test 
In the event of clinically significant findings, the set of examinations must be repeated 
approximately every [ADDRESS_423115] be recorded as AEs in the eCRF.   
Neurological examinations are recorded on the eCRF . 
[IP_ADDRESS] Epworth Sleepi[INVESTIGATOR_7110]© 
The ESS© is a validated questionnaire designed to provide a subjective measure of daytime 
sleepi[INVESTIGATOR_008] [Johns 1991 ]. The ESS© [see Appendix 12 ] will be self -administered at site 
visits (V isit 1, Visit 2, Visit 3, Visit 6, Visit 8, and V isit 10) on a hand- held device to assess 
daytime sleepi[INVESTIGATOR_008]. All clinically significant findings must be recorded as AEs in the eCRF . 
[IP_ADDRESS] ECG assessment  
A standard 12- lead ECG is to be performed at Visit 1, in the second morning of Visit 3, 
Visit [ADDRESS_423116] in the supi[INVESTIGATOR_2547]. Data records 
will be sent to the evaluation center for central reading.  
Details will be provided in the 12- lead ECG laboratory manual.  
The following parameters will be evaluate d: PQ or PR (ms), QRS (ms), QT (ms), heart rate 
(HR; bpm), and rhythm. QTc (ms) will be calculated according to: 
• Bazett ’s formula: QTcB = QT / (RR)1/2 
and 
• Fridericia’ s formula: QTcF = QT / (RR)1/3, where RR = 60 / HR 
If the central review of the ECG detect s a prolonged QTcB and/or QTcF interval greater 
than [ADDRESS_423117] at screening (Visit 1 or Visit 3), the ECG must be repeated (at 
least [ADDRESS_423118] ECG). If the central review confirms that the repeated ECG shows 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 79/[ADDRESS_423119] 2017 -004642 -20 
Doc No D- 18.160 
 
 a QTcB and/or QTcF interval greater than [ADDRESS_423120] be recorded in the eCRF.  
ECG data collected by [CONTACT_341808].  
7.2.4 Patient preferences questionnaire 
The DCE methodology requires the presentation of several possible comparative scenarios, 
(i.e., Treatment A and Treatment B) showing specific treatment outcomes  (benefits and 
risks). After eac h treatment scenario , subjects will be asked to make choices about the type 
of treatment they would be willing to take. The patient preferences questionnaire is programmed on the tablet site device in the subject ’s language (i.e. , US English for [LOCATION_003]  
and German for Ge rmany), and if subject s consent to participate to this sub -study, must be 
completed at Randomization (V isit 4) and at EODBT visit (V isit 8, 2
nd morning ). 
For further details, see Appendix 14.  
7.2.5 Laboratory assessments 
[IP_ADDRESS] Type of laboratory 
A central laboratory (see central laboratory manual for contact [CONTACT_8972]) will be used for all protocol- mandated laboratory tests  until EOS , including follow-up tests due to abnormal 
laboratory findings and laboratory tests performed at unscheduled visits. 
Local laboratory results of the parameters described in Section [IP_ADDRESS] will only be 
collected in exceptional circumstances (e.g., hospi[INVESTIGATOR_42860] a medical 
emergency).  The local laboratory results (with the corresponding normal ranges) must be 
recorded in the eCRF . 
If a central  laboratory sample is lost or cannot be analyzed for whatever reason, it is 
recommended to the investigator to collect an additional sample as soon as possible for repeat analysis . 
No repeat test is allowed if the subject does not meet the eligibility criter ia. 
Central laboratory reports will be sent to the investigator. In the event of specific (pre-defined) laboratory abnormalities, the central laboratory will alert Idorsia  personnel 
and the concerned site personnel. 
All laboratory re ports must be reviewed, signed, and dated by [CONTACT_42920] 10 working days of receipt and filed with the source documentation. The 
investigator/delegate must indicate on the laboratory report whether abnormal values are 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 80/[ADDRESS_423121] be reported as an AE or SAE as appropriate [see Section  9], and must be followed up until the 
value returns to within the normal range or is stable, or until the change is no longer clinically significant. 
Details about the collection, sampling, storage, shipment procedures, and reporting of 
results and abnormal findings can be found in the laboratory manual. Blood samples will be drawn under fasted condit ion (i.e., before breakfast) at Visit 3, Visit 6 , Visit 7  and 
Visit 8. 
[IP_ADDRESS] Laboratory tests 
Hematology  
• Hemoglobin  
• Hematocrit  
• Erythrocytes  
• Reticulocyte  
• Leukocytes with differential counts  
• Platelets  
Clinical chemistry  
• ALT  
• AST  
• Alkaline phosphatase  
• Creatine kinase  
• Total and direct bilirubin  
• Gamma -glutamyl transferase  
• Creatinine and c reatinine clearance  
• Blood urea nitrogen  
• Uric acid  
• Glucose  
• Cholesterol, triglycerides  
• Sodium, potassium, chloride, calcium  
• Albumin  
• Thyroid hormones, i.e., triiodothyronine (total and free) and thyroxine (total and free), 
and thyroid- stimulating hormone.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 81/[ADDRESS_423122] for women of childbearing potential will be performed at Screening 
(Visit 1) and on the second morning of Visit 8. A urine pre gnancy  test will be performed 
on Visit 2, Visit 4, on the first evening of Visit 6, Visit 7  and at run -out (Visit 10). If 
pregnancy is suspected during the study, a serum pregnancy test must be performed 
immediately.  
Other tests  
The urine drug screening kits (testing for presence of benzodiazepi[INVESTIGATOR_1651], barbiturates, cannabinoids, opi[INVESTIGATOR_858], amphetamines , phencyclidine or cocaine) and the breathalyzer for 
alcohol detection in the exhaled breath will be provided by [CONTACT_2237]. Should 
any technical issue arise with the breathalyzer,  alcohol saliva tests will be provided to be 
used as back -up.  
Study drug is administered as described in Section  5 only if the results of the pregnancy 
tests and other tests are negative.  
7.2.6 Pharmacokinetic assessments  
PK samples will be collected in the morning after the second PSG night, after lights on, 
approximately 9 –[ADDRESS_423123] -dose (i.e., 30–90 min after lights on) at Visit 6 and Visit 8 or in 
the event of excessive sleepi[INVESTIGATOR_223133]’s opi[INVESTIGATOR_1649]. 
The date and the time of blood sample collection will be entered in the eCRF. The date and 
time of the last study treatment dosing before blood draw will be entered in the eCRF. The 
site personnel will ship the plasma samples to the central laboratory. The c entral laboratory 
will ship the samples to Idorsia Drug Metabolism and Pharmacokinetics d epartment, who 
are in charge of the PK sample analysis.  
Details about the collection, sampling, storage, and shipment procedures can be found in the laboratory manual . 
[ADDRESS_423124]-STUDY TREATMENT / 
MEDICAL CARE 
8.[ADDRESS_423125] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 82/[ADDRESS_423126] 2017 -004642 -20 
Doc No D- 18.160 
 
 withdraw further participation in all components of the study (i.e., withdrawal of consent), 
die, or are lost to follow- up. If a subject withdraws consent, no further data will be collected 
in the eCRF from the date of withdrawal onward. Withdrawal from the study may also 
result from a decision by [CONTACT_341809], including premature termination or 
suspension of the study. 
Subjects are considered as lost to follow -up if all reasonable attempts by [CONTACT_42922]. The site must take preventive measures to avoid 
a subject being lost to follow -up (e.g., document different ways of contact [CONTACT_42923], home address, email address, person to be contact[CONTACT_42924]). If the subject cannot be reached, the site must make a reasonable effort to contact [CONTACT_423], document all attempts, and enter the loss of follow -up information 
into the eCRF. The f ollowing methods must be used:  at least three telephone calls must be 
placed to the last available telephone number and one registered letter must be sent by [CONTACT_215253] . Additional methods may be acceptable if they are 
compliant with local rules/regulations  (e.g., a visit by [CONTACT_42926] ’s home), 
respecting the subject ’s right to privacy. If the subject is still unreachable after all contact 
[CONTACT_42927], he/she will be considered to be lost to follow-up. 
If premature withdrawal occurs for any reason, the reason (if known) for premature 
withdrawal from the study  (e.g. , withdrawal by [CONTACT_1130], AE, lost to follow -up, death) must 
be recorded in the eCRF.  
If, for whatever reason (except death or loss -to-follow-up), a subject is withdrawn from the 
study, the investigator should make efforts to schedule a last appointme nt / telephone call 
to assess the safety and well -being of the subject, collect unused study treatment and 
discuss follow -up medical care. Data obtained during this last appointment  / telephone call 
will be recorded in the subjects ’ medical records but it will not be collected in the eCRF. 
The investigator must provide follow -up medical care for all subjects who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care, as described in Section 8.4. 
8.3 Premature termination or suspension of the study 
Idorsia  reserves the right to terminate the study at any time globally or locally. Investigators 
can terminate the participat ion of their site in the study at any time.  
If the study is prematurely suspended or terminated, Idorsia  will promptly inform the 
investigators, IECs/IRBs  and health au thorities, as appropriate, and provide the reasons for 
the suspension or termination. 
If the study is suspended or prematurely terminated for any reason, the investigator  – in 
agreement with Idorsia – must promptly inform all enrolled subjects and ensure their 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 83/[ADDRESS_423127] 2017 -004642 -20 
Doc No D- 18.160 
 
 appropriate treatment and follow -up, as described in Section  8.4. Idorsia may inform the 
investigator of additional procedures to be followed in order to ensure that adequate 
consideration is given to the protection of the subjects’ interests.  
In addition, if the investigator suspends or terminates  the participation in  the study without 
prior agreement from Idorsia , the investigator must promptly inform Idorsia personnel and 
the IEC/IRB, and provide both with a detailed written explanation of the termination or suspension. 
If the IEC/IRB suspends or terminates its approval  / favorable opi[INVESTIGATOR_23748], the 
investigator must promptly notify Idorsia  personnel and provide a detailed written 
explanation of the termination or suspension. 
8.4 Medical care of subjects after study completion / withdrawal from study 
After the subject ’s study completion or premature withdrawal from the study, whichever 
applies, the investigator/delegate will explain to subjects what treatment / medical care is 
necessary and available according to local regulations.  
[ADDRESS_423128] 
during the course of the study, whether or not considered by [CONTACT_86190].  
A TEAE is any AE temporally associated with the use of study treatment (i.e., emerging from DB study treatment initiation until up to 30 days after DB study treatment discontinuation or until enrollment into the extension study) whether or not considered b y 
the investigator as related to study treatment. 
AEs include: 
• Exacerbation of a pre- existing disease.  
• Increase in frequency or intensity of a pre- existing epi[INVESTIGATOR_42861]. 
• Disease or medical condition detected or diagnosed during the  course of the study even 
though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present at study start that worsen following 
the signing of informed consent. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 84/[ADDRESS_423129] 2017 -004642 -20 
Doc No D- 18.160 
 
 • Abnormal assessments, e.g., change on physical examination, ECG findings, if they 
represent a clinically significant finding that was not present at study start or worsened 
during the course of the study. 
• Laboratory test abnormalities if they represent a clinically significant finding, symptomatic or  not, which was not present at study start or worsened during the course 
of the study, or led to interruption or permanent discontinuation of study treatment. 
Overdose, misuse, abuse of the study treatment and study treatment errors will be reported as an AE. 
The ISB will adjudicate treatment -emergent AESIs which are similar to, or indicate: 
• narcolepsy -like symptoms (i.e. , EDS, cataplexy and complex sleep behavior events 
including hallucinations/sleep paralysis)  
• suicide/self -injury 
A treatment -emergent AESI  is any AESI emerging from DB study treatment initiation until 
up to 30 days after DB study treatment discontinuation or until enrollment into the extension study. 
9.1.2 Intensity of adverse events  
The intensity of clinical AEs is graded on a three -point scale – mild, moderate, severe – 
and is reported on specific AE pages of the e CRF.  
Any increas es in intensity of an AE during the study will be reported in the eCRF.
  
The three categories of intensity are defined as follows:  
 Mild  
The event may be noticeable to the subject. It does not usually influence daily activities, 
and normally does not require intervention. 
 Moderate  
The event may make the subject uncomfortable. Performance of daily activities may be influenced, and intervention may be needed. 
 Severe  
The event may cause noticeable discomfort and usually interferes with daily activities. The subject may not be able to continue in the study, and treatment or intervention is usually needed.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 85/[ADDRESS_423130] 2017 -004642 -20 
Doc No D- 18.160 
 
 A mild, moderate, or severe AE may or may not be serious [see Section 9.2.1 ]. These terms 
are used to describe the intensity of a specific event. Medical judgment should be used on 
a case -by-case basis.  
Seriousness, rather than intensity assessment, determines the regulatory reporting obligations. 
9.1.[ADDRESS_423131] be recorded on AE pages of the eCRF.  
All AEs with an onset date after signing of informed consent , and up to enrollment in the 
ID-078A303 (i.e., ID -078A301 EO T) for subjects that are participating in the extension 
study, must be recorded on AE pages of the ID-078A301 eCRF. 
9.1.[ADDRESS_423132] ’s EOS telephone call will not be collected by [CONTACT_42944].  
For subjects enrolled in ID -078A303, AEs that are ongoing at ID -078A301 EO T will be 
followed up in the extension study and reported in the ID -078A303 eCRF on a dedicated 
page. 
9.[ADDRESS_423133] one of the following 
criteria:  
• Fatal.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 86/[ADDRESS_423134] 2017 -004642 -20 
Doc No D- 18.160 
 
 • Life-threatening: Refers to an event in which the subject was at risk of death at the time 
of the event. It does not refer to an event that hypothetically might have caused death 
had it been more severe.  
• Requiring in-patient hospi[INVESTIGATOR_1081]. 
• Resulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Medi cally significant: Refers to important medical events that may not immediately 
result in death, be life -threatening, or require hospi[INVESTIGATOR_42862], based upon appropriate medical judgment, they may jeopardize the 
subject,  and may require medical or surgical intervention to prevent one of the outcomes 
listed in the definitions above. 
The following reasons for hospi[INVESTIGATOR_42863]: 
• Hospi[INVESTIGATOR_180458], or social and/or convenience reasons. 
• Hospi[INVESTIGATOR_5912] -planned (i.e., planned prior to signing informed consent) surgery 
or standard monitoring of a pre -existing disease or medical condition that did not 
worsen, e.g., hospi[INVESTIGATOR_42865] a subject wi th stable angina 
pectoris.  
However, complications that occur during hospi[INVESTIGATOR_42866] (e.g., if a complication prolongs hospi[INVESTIGATOR_059]). 
9.2.[ADDRESS_423135] be reported on AE 
pages in the eCRF and on an SAE form, regardless of the investigator -attributed causal 
relationship with study treatment or study -mandated procedures.  
All SAEs with an onset date after signing of informed consent and up to enrollment in 
ID-078A303 (i.e., ID -078A301 EO T) for subjects that are participating in the extension 
study must be recorded on AE pages of the ID-078A301 eCRF. 
An SAE is defined as related to protocol -mandated procedures if it appears to have a 
reasonable possibility of a causal relationship to either the study design or to 
protocol- mandated procedures (e.g., discontinuation of a subject ’s previous treatment 
during a washout period, leading to exacerbation of underlying disease). 
9.2.[ADDRESS_423136] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 87/[ADDRESS_423137] ’s EOS telephone call must be reported to Idorsia Global Drug Safety, but 
it is not recorded in the eCRF. 
For subjects enrolled in ID -078A303, SAEs that are ongoing at ID -078A301 EO T will be 
followed up in the extension study and reported in the ID -078A303 eCRF on a dedicated 
page. 9.2.[ADDRESS_423138] be reported to Idorsia  Global 
Drug Safety within 24 hours of the investigator ’s knowledge of the event, only if 
considered by [CONTACT_341810] y 
treatment.  
9.2.[ADDRESS_423139] be reported by [CONTACT_42931] 
24 hours of the investigator’ s first knowledge of the event.  
All SAEs must be recorded on an SAE form, irrespective of the study treatment received 
by [CONTACT_423], and whether or not this event is considered by [CONTACT_341811].  
The SAE forms must be sent to Idorsia Global Drug Safety  (contact [CONTACT_42932]). The investigator must comple te the SAE form in English, and must 
assess the event ’s causal relationship to the study treatment.  
Any relevant information from source documents regarding the SAE, e.g., hospi[INVESTIGATOR_215181], etc., must be summarized on the SAE form. 
Follow-up information about a previously reported SAE must also be reported within 
[ADDRESS_423140] is hospi[INVESTIGATOR_42868] a hospi[INVESTIGATOR_341781], it is the investigator ’s 
responsibility to contact [CONTACT_42933][INVESTIGATOR_42870] -relevant information and 
documentation. The expectedness of an adverse reaction is determined by [CONTACT_42934] (RSI) section  provided in the most recent version of the IB  for ACT -541468 
[ACT -541468 IB]. Any SAE that is assessed as related and unexpected against the RSI of 
the A CT-541468 IB [ACT -541468 IB] is known as a S[LOCATION_003]R and must be reported by 
[CONTACT_341812] (including the EudraV igilance  database if the study 
is conducted in Europe), IECs/IRBs and investigators. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 88/[ADDRESS_423141], any pregnancy occurring after study 
start (i.e., sign ing of informed consent) up to EOS  must be reported within 24 hour s of the 
investigator ’s knowledge of the event. 
Pregnancies must be reported on the Idorsia  Pregnancy form, which is faxed to Idorsia  
Global Drug Safety (see contact [CONTACT_42936]), and on an AE 
page in the e CRF.  
9.3.[ADDRESS_423142] be reported on an SAE form as described in 
Section  9.2.5. 
9.4 Study safety monitoring 
Study safety information (AEs, SAEs, laboratory values, ECGs, vital signs, and study- specific examinations as required) is monitored and reviewed on a continuous basis 
by [CONTACT_42937] (in charge of ensuring subjects ’ safety as well as data quality) . 
In addition, an IDMC and an ISB are monitoring safety data [ see Section  3.3]. 
10 STATISTICAL METHODS 
All statistical analyses will be conducted by [CONTACT_341813].  
A Statistical Analysis Plan (SAP) will provide full details of the analyses, data displays, and algorithms to be used for data derivations. 
10.[ADDRESS_423143] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 89/[ADDRESS_423144] 2017 -004642 -20 
Doc No D- 18.160 
 
 10.1.2 Full Analysis Set  
The Full Analysis Set (FAS) includes all subjects assigned to a DB study treatment. In 
order to adhere to the intention- to-treat principle as much as possible: 
• Subjects are evaluated according to the treatment and strata they have been assigned 
to, which m ay differ from t he treatment they have received;  
• All available data are included.  
10.1.3 Per-Protocol Set  
The Per -Protocol Set (PPS) comprises all subjects from the FAS  who complied with the 
protocol sufficiently to be likely to exhibit the treatment effects. Criteria for sufficient 
compliance include exposure to treatment, availability of measurements , and absence of 
major protocol deviations that have an impact on the treatment effect. The full list of criteria will be finalized  before  unblinding treatment codes. 
10.1.[ADDRESS_423145] one dose of DB study treatment.  
Subjects will be evaluated according to the actual treatment they received, which may differ from the randomly assigned treatment. 
10.1.5 Treatment W ithdrawal Set 
The Treatment W ithdrawal Set comprises all subjects included in the Safety Set who 
received single-blind placebo treatment in the run-out period. 10.1.6 Pharmacokinetic Analysis Set  
The Pharmacokinetic Analysis Set  (PK Set)  includes all subjects in the Safety Set who 
have at least [ADDRESS_423146] one patient preferences questionnaire after initiation of study treatment. 
10.1.8  Usage of the analysis sets 
The analyses of efficacy endpoints  including baseline and disease characteristics  will be 
performed using the FAS, and the PPS for certain sensitivity analyses. 
The Safety Set  will be used for the analysis of safety endpoints  (including previous and 
concomitant medications,  and study treatment exposure). 
Subject data will be listed  using the Safety Set, unless otherwise specified.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 90/[ADDRESS_423147] 2017 -004642 -20 
Doc No D- 18.160 
 
 The Treatment Withdrawal Set will be used for the analysis of  endpoints used to assess 
withdrawal symptoms (e.g., BWSQ total score ) and  rebound insomnia (e.g. , objective and 
subjective sleep parameters : WASO, LP S, TST, sWASO, sLSO , and sTST). 
The analysis of ACT -541468 plasma concentrations 9–[ADDRESS_423148] -dose will be performed 
using the PK  Set. 
The Patient Preferences Analysis Set will be used for the analysis of endpoints  to assess 
patient preferences.  
10.2 Variables 
Detailed description of study efficacy and safety variables (endpoints) can be found in 
Section 6 of this protocol.  
10.3 Description of statistical analyses 
10.3.1 Analysis of the primary and secondary efficacy variables 
[IP_ADDRESS] Overall testing strategy  
The Type I error rate will be controlled for the testing of multiple null hypotheses 
associated with the primary and secondary endpoints assessed at 1 and 3 months of 
treatment  and the two  dose levels included in this study, i.e., 25 mg and 50 mg. 
The eight  statistical null hypotheses associated with the primary efficacy endpoints are:  
Sleep maintenance:  
• H1WASO : High er Dose – Placebo = 0 for WASO at Month 1 
• H2WASO : High er Dose – Placebo = 0 for WASO at Month 3 
• H3WASO : Low er Dose – Placebo = 0 for WASO at Month 1 
• H4WASO : Low er Dose – Placebo = 0 for WASO  at Month 3 
Sleep onset:  
• H1LPS: High er Dose – Placebo = 0 for LPS at Month 1 
• H2LPS: High er Dose – Placebo = 0 for LPS at Month 3 
• H3LPS: Low er Dose – Placebo = 0 for LPS at Month 1 
• H4LPS: Low er Dose – Placebo = 0 for LPS at Month 3 
The eight statistical null hypotheses associated with the secondary efficacy endpoints are:  
Sleep quantity: 
• H1sTST: High er Dose – Placebo = [ADDRESS_423149] at Month 1 
• H2sTST: High er Dose – Placebo = [ADDRESS_423150] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 91/[ADDRESS_423151] 2017 -004642 -20 
Doc No D- 18.160 
 
 • H3sTST: Low er Dose – Placebo = [ADDRESS_423152] at Month 1 
• H4sTST: Low er Dose – Placebo = [ADDRESS_423153] at Month 3 
Next day performance:  
• H1IDSIQ: High er Dose – Placebo = 0 for IDSIQ sleepi[INVESTIGATOR_223135] 1 
• H2IDSIQ: High er Dose – Placebo = 0 for IDSIQ sleepi[INVESTIGATOR_223135] 3 
• H3IDSIQ: Low er Dose – Placebo = 0 for IDSIQ sleepi[INVESTIGATOR_223135] 1 
• H4IDSIQ: Low er Dose – Placebo = 0 for IDSIQ sleepi[INVESTIGATOR_223135] 3 
where ‘Higher Dose ’, ‘Lower Dose ’, and ‘ Placebo ’ represent  the mean change from 
baseline for the given endpoint (WASO, LPS, sTST or IDSIQ sleepi[INVESTIGATOR_223115]) 
and time  point (Month 1 or Month 3)  for the [ADDRESS_423154] the alternative hypothesis: that ACT -541468 
improves WASO  / LPS / sTST / IDSIQ sleepi[INVESTIGATOR_341782]  (25 or 
50 mg)  and time  point (Month 1 or Month 3) compared to placebo. 
The order of testing and the alpha level applied to each null hypothesis will be based on 
the Bonferroni -based gatekeepi[INVESTIGATOR_124502] [Bretz  2009 ] (shown in Figure 2 below as a 
directed graph) that will control the study -wise Type I error at a two -sided 5% significance 
level. To account for the concurrent evaluation (multiple comparison) of two distinct 
endpoint categories (i.e., sleep maintenance and sleep onset) a Bonferroni correction is 
applied. Both endpoint categories will be tested at half of the two- sided 5% significance 
level. This supports the sponsor’ s intention  to make a superiority claim versu s placebo for 
efficacy in either a sleep maintenance and/or sleep onset indication. The remaining 
hypotheses will be tested following the gatekeepi[INVESTIGATOR_223137] [ADDRESS_423155] -541468 vs placebo. The pre -specified proportion of alpha that will be 
distributed once a given null hypothesis (node) is rejected is shown on the arrow in the directed graph. If a certain null hypothesis cannot be rejected, then the  alpha level used for 
that test is absorbed at that node and not distributed further. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 92/[ADDRESS_423156] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 93/[ADDRESS_423157] 2017 -004642 -20 
Doc No D- 18.160 
 
 [IP_ADDRESS] Hypotheses and statistical model 
The main  analysis will be performed  using the FAS. 
A longitudinal data analysis method (i.e., linear mixed effects model) will be used for the 
analysis of change from baseline in WASO, LPS, sTST, and IDSIQ scores, separately.  All 
available data, regardless of occurrence of intercurrent events (e.g., study treatment 
discontinuation, the use of prohibited medication), will be included in the model. 
The analysis model will adjust for the baseline value of the relevant response variable 
(either WASO, LPS, sTST or IDSIQ sleepi[INVESTIGATOR_223115]), age group (<  65; 
≥ 65 years), treatment (high er dose; low er dose; placebo), time point (Month 1; Month 3), 
and the interaction of treatment by [CONTACT_221934] , and baseline by [CONTACT_221934]. 
To evaluate the efficacy hypotheses, appropriate contrasts will be used to test the treatment 
differences of interest (i.e., the difference in Least Squares  mean change from baseline 
between higher dose ACT -[ADDRESS_423158] -541468 vs placebo at 
Month 1 and Month 3). An unstructured covariance matrix will be used to model the 
correlation among repeated measurements. This approach relies on the missing at random (MAR) assumption. 
A term for ‘center ’ is not included in the statistical model due to the low numbers of 
subjects expected in many centers. Randomization was not stratified by [CONTACT_223195].  
[IP_ADDRESS] Handling of missing data 
For WASO and LPS values, if one of the two values is missing either for baseline, Month [ADDRESS_423159] 4 days of data during each week to calculate a weekly mean. Otherwise, the mean value will be considered missing for that week. 
Note that the above implies implicit imputation: the missing data point(s) is(are) give n the 
same value as the mean of the non -missing data point(s) of that same week or time point. 
[IP_ADDRESS] Supportive/sensitivity analyses  
The impact of deviations from the MAR assumption underlying  the linear mixed effects 
model as well as the incidence and pattern of missing values will be explored in order to 
evaluate the possible impact on results and will be described in the SAP. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 94/[ADDRESS_423160] on the results. 
10.3.2 Analysis of other efficacy variables 
Summary statistics will be provided for other efficacy endpoints using either number (%) 
of subjects for categorical variables or descriptive statistics  (e.g., mean, SD, median, min ., 
max.) for continuous variables. Further details will be described in the SAP.  
10.3.3 Analysis of the safety variables 
Analyses  of safety endpoints  will be performed using  the Safety Set, unless noted 
otherwise. Adverse events  
AEs will be coded using MedDRA. The number (%) of subjects experiencing a TEAE 
(including SAEs, AESIs after adjudication by [CONTACT_42892], and AEs leading to premature 
discontinuation of the DB study treatment) will be summarized by [CONTACT_1196] 
(SOC) and/or PT, and maximum intensity. A subject with multiple intensities reported for an AE will be summarized under the maximum intensity recorded for the event. A subject 
with multiple occurrences of an AE is counted only once in the AE category (e.g., SOC, PT). 
Laboratory data 
Laboratory analyses will be based on data received from the central laboratory. Observed  
values and changes from b aseline to Month 1 and Month 3 in both hematology and blood 
chemistry laboratory parameters  will be summarized.  The number (%) of su bjects having 
a marked laboratory abnormality  during DB study tre atment  will be tabulated.  
Vital signs  and weight  
Observed values and changes from baseline to Month 1 and Month 3 in vital signs (mean 
of the two PSG nights in systolic and diastolic BP , and  pulse rate) will be summarized.  
Observed values and  changes from baseline to Month 3 in body weight will be summar ized.  
Electrocardiograms  
Observed values and change s from baseline to Month 3 for each ECG parameter (QT cB, 
QTcF , heart rate, PR, QRS) will be summarized. The number (%) of subjects having a 
marked ECG abnormality during DB  study treatment will be tabulated.  
Withdrawal symptoms The Treatment Withdrawal Set will be used to assess the potential for withdrawal 
symptoms.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 95/[ADDRESS_423161] assessment on D B treatment (Visit 8, 2nd morning) to the 
beginning and the end of the treatment withdrawal period (in the morning at Visit 9 and at Visit 10, respectively).  
In addition, withdrawal symptoms after DB study treatment withdrawal will be assessed through the incidence of AEs and marked ECG abnormalities occurring during the treatment withdrawal period. The number (%) of subjects having, separately, an AE and a marked ECG abnormality during the treatment withdrawal period will be tabulated . 
Insomnia rebound eff ect 
The Treatment Withdrawal Set will be used to assess the potential for rebound insomnia. 
The changes from baseline to the treatment withdrawal period (V isit 9, run-out ) in 
objective sleep parameters ( WASO, LPS  and TST)  will be summarized using descriptive 
statistics.  
The changes from baseline (mean value based on the screening sleep diary entries performed at home  in the [ADDRESS_423162] PSG at Visit 3) to the 
treatment withdrawal period (after PSG night at Visit 9) in subjective sleep parameters 
(sWASO, sLSO, and sTST) will be summarized using descriptive statistics . 
Next -day residual effect  
Observed values and changes from baseline to Month [ADDRESS_423163]
©, 
SDS©, and VAS scores (mm) assessing morning sleepi[INVESTIGATOR_008], daytime alertness and daytime 
ability to function, will be summarized.  
C-SSRS© 
Number (%) of subjects with suicidal ideation, suicidal behavior, and/or self -injurious 
behavior without suicidal intent based on the C -SSRS© during DB treatment will be 
tabula ted. 
Shifts from baseline showing any changes in suicidal ideation and suicidal behavior during DB treatment will also be provided. Subjects will be summarized under the worst of the 
following three categories, shown here in the order from best to worst: 1) No suicidal ideation or behavior, 2) Suicidal ideation only, and 3) Suicidal ideation and behavior. 
10.3.4 Analysis of pharmacokinetic variables 
PK analyses will be performed using the PK S et. 
Descriptive statistics (n, mean, standard deviation, coefficient of variation [CV%], m 
[number of non- zero concentrations], geometric mean, geometric standard deviation, 
geometric CV%, median, minimum and maximum) of the ACT -[ADDRESS_423164] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 96/[ADDRESS_423165] 2017 -004642 -20 
Doc No D- 18.160 
 
 concentrations collected approximately 9 –[ADDRESS_423166] -dose (morning after the second PSG 
night) at Visit 6 and Visit 8 will be provided. 
Exposure-safety analysis 
The exposure -safety relationship will be explored using C 9–10h (plasma concentrations of 
ACT -541468 in the morning after the second PSG night at V isit 6 and V isit 8) and will be 
based on the PK S et. Safety parameters considered for this analysis will likely include 
selected AEs (e.g., somnolence), changes from baseline in Coding sub- test©, SDS©, VAS 
scores (mm) assess ing morning sleepi[INVESTIGATOR_008], daytime alertness and daytime ability to 
function, and other parameters as relevant.  Further details will be described in the SAP. 
10.3.5 Subgroup analyses 
Subgroup analyses will be conducted to explore the uniformity of the overall treatm ent 
effects with regards to efficacy and safety variables , and will be described in the SAP. 
10.3.6 Analysis of the patient preferences variable 
Discrete choice data from the PAUSe sub -study will be analyzed using multinomial logit, 
random parameter log it, latent c lass and heteroscedastic conditional logit models. 
Socio -demographic and clinical characteristics, and health literacy and numeracy data will 
be collected from the study participants, and used as covariates for assessing preference 
and scale heterogeneit y. The results of the DCE may be used to specify the weights and 
partial value functions in a quantitative benefit -risk assessment (BRA) of insomnia 
treatments. The BRA will be run both deterministically and probabilistically and will facilitate a stochast ic multicriteria acceptability analysis (SMAA). The SMAA will involve 
running up to 10,000 iterations of the BRA, each time sampling weights and performance inputs from pre -specified distributions. Further details on analysis of the PAUSe  sub- study 
will be provided in a separate SAP . 
10.4 Interim analyses 
No formal interim analysis will be performed for determining whether to stop (or modify) the study early (i.e., no hypothesis testing will be conducted ad interim ). Therefore, no 
adjustment for multiple testing is required. This study includes an IDMC and ISB that will assess the safety of ACT -541468 on a regular basis as per the IDMC and ISB charter s, 
respectively. To support the review of the safety and efficacy data by [CONTACT_31849], blinded data will be  provided by [CONTACT_42944] (or designated CRO) for the open sessions, and unblinded 
data will be provided by [CONTACT_223196]. 
10.[ADDRESS_423167]-541468 
Insomnia disorder 
Protocol ID-078A301 
Version 4 30 Jul
y 2018, pa ge 98/[ADDRESS_423168] 90%  power to detect an effect 
size of 0.[ADDRESS_423169] of testing multiple null hypotheses on power at  a given sample 
size 
 
11 DATA HANDLING 
11.1 Data collection 
The investigator/delegate is responsible for ensuring the accur acy, completeness and 
timeliness of the data reported. All source documents are recom mended to be completed 
in a neat, legible manner to ensure accurate inter pretation of the data. Data reported in the 
eCRF derived from source documents must be consistent with the source documents. 
eCRF data will be reported through electronic data capture (a w eb-based tool). The 
investigator and site personnel will be trained to enter and ed it the data via a secure 
network, with secure access features (username, password, and identification – an 
electronic password system). A c omplete electronic audit trail will be maintained. The 5060708090100Effect size = 0.37
Number of independent null hypothesesPower (%)based on two-sample z-test (alpha = 2.5% two-sided)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20N = 350 per group
N = 300 per group
N = [ADDRESS_423170] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 99/[ADDRESS_423171] 2017 -004642 -20 
Doc No D- 18.160 
 
 investigator/delegate will approve the data (i.e., confirm the accuracy of the data recorded) 
using an electronic signature (ref. to US 21 CFR Part 11). 
Entries recorded by [CONTACT_42918]- held device (i.e., ESS©, sleep diary , VAS, ISI©, 
IDSIQ, PGA-S daytime symptoms , PGI -C daytime and night -time symptoms , PGI-S 
night- time symptoms , SDS©, BWSQ ) and on paper (i.e., Coding sub- test©) as well as the 
physician -reported global assessment on a tablet  at site (i.e., C -SSRS©, MMSE©, PAUSe ) 
and on paper (i.e., MINI©) are considered source data. Site personnel will review and 
ensure completeness and readability of the subjects ’ entries.  Site personnel will be allowed 
to instigate co rrection or deletion of subject  metadata or answers in physician -reported 
assessments. Site personnel will not be allowed to alter subject -generated data. A data 
correction form will be completed by [CONTACT_341814]. 
Subject  screening and enrollment data will be completed for all subjects (i.e., eligible and 
non-eligible) through the IRT system and eCRF.  
For each subject enrolled, regardless of study treatment initiation, a n eCRF must be 
completed and signed by [CONTACT_093]/delegate. This also applies to those subjects who 
fail to complete the study. If a subject withdraws from the study, the reason must be noted 
on the e CRF.  
11.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On eCRFs or 
other documents (e.g., documents attached to SAE forms / Pregnancy forms) submitted to Idorsia and any CROs, subjects mu st be identified only by [CONTACT_341815], date of birth , hospi[INVESTIGATOR_42871], or any other identifier. The investigator/delegate 
must keep a subject identification code list at the site, showing the screening/randomization number, the subject ’s name, date of birth, and address or any other locally accepted 
identif iers. Documents identifying the subjects (e.g., signed ICFs) must not be sent to 
Idorsia , and must be kept in strict confidence by [CONTACT_093]/delegate. 
11.[ADDRESS_423172] status at any time  point during the course of the 
study.  
While entering the data, the investigator/delegate will be instantly alerted to data queries by [CONTACT_42940]. Additional data review will be performed by [CONTACT_341816] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 100/[ADDRESS_423173] 2017 -004642 -20 
Doc No D- 18.160 
 
 monitoring. If discrepant data are detected, a query specifying the problem and requesting 
clarification will be issued and visible to the investigator/delegate via the eCRF. All 
electronic queries visible in the system either require a data correction (when applicable) and a response from  the investigator/delegate to clarify the queried data directly in the 
eCRF, or simply a data correction in the e CRF.  
This process will continue until database closure. 
The investigator/delegate must, on request, supply Idorsia with any required background 
data from the study documentation or clinical records. This is particularly important when errors in data transcription are suspected. In the event  of health authority queries, it is also 
necessary to have access to the complete study records, provided t hat subject 
confidentiality is protected.  
Laboratory samples , ECGs, PSGs and hand- held device data will be processed through a 
central laboratory / CRO and the results will be electronically sent to Idorsia. 
If local laboratory data is obtained, as may be required per protocol in certain instances, it 
must be entered in the eCRF by [CONTACT_14523].  
AEs are coded according to the latest version of MedDRA  used by [CONTACT_42944]. 
After the database has been declared complete and accurate, the database will be locked . 
Any changes to the database after that time may only be made as described in the appropriate Idorsia QS doc ument s. After database closure, the investigator will receive the 
eCRFs of the subjects of his/her site (including the audit trail) on electronic  media or as a 
paper copy.  
12 PROCEDURES AND GOOD CLINICAL PRACTICE 
12.1 Ethics and Good Clinical Practice 
Idorsia  personnel and the investigators will ensure that the study is conducted in full 
compliance with ICH -GCP Guidelines, the principles of the “Declaration of Helsinki” , and 
with the laws and regulations of the country in which the study is conducted. 
12.2 Independent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related document(s) provided to the subject (such as the I CF) to an IEC/IRB. Approval from the committee/board must be 
obtained before starting the study, and must be documented in a dated letter to the investigator, clearly identifying the study, the documents reviewed, and the date of approva l. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 101/[ADDRESS_423174] also be 
submitted as amendments by [CONTACT_42942]/IRB in accordance with local 
procedures and regulations [see Section 12.6].  
A list of members participating in the IEC/IRB meetings must be provided, including the names, qualifications, and functions of these members. If that is not possible, the attempts made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation.  
If a member of the study personnel was present during an IEC/IRB meeting, it must be 
clear that this pers on did not vote. 
12.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to ICH-GCP and Declaration of Helsinki guidelines and local regulations from each 
individual participating in this study. The investigator/delegate must explain to subjects 
that they are completely free to refuse to enter the study, or to voluntarily withdraw from the study at any time for any reason without having to provide any justification. Special attention shall be paid to the information needs of specific subject populations and of individual subjects, as well as to the methods used to give the information. Adequate time shall be given for the subject to consider his or her decision to participate in the study and it shall be verified that the subject has understood the information (e.g., by [CONTACT_42943]). 
The ICF will be provided in the country local language(s). Site personnel authorized (according to local regulation) to participate in the consent 
process and/or to obtain consent from the subject will be listed on the Delegation of 
Authority (DoA) form supplied by [CONTACT_42944] . A study physician must always be involved in 
the consent process.  In European countries, the informed consent must be obtained by a 
physician.  
The subject and authorized site personnel listed on the DoA form supplied by [CONTACT_42945], personally date, and time (if the first study -mandated procedure is to be performed on 
the same day informed consent is obtained) the ICF before any study -related procedures 
(i.e., any procedures required by [CONTACT_760]) begin.  
A copy of the signed and dated ICF is given to the subject , the original is filed in the site 
documentation. The informed consent process must be fully documented in the subject ’s 
medical records. This must include at a minimum the study reference, the subject number, 
the date and, if applicable, time when the subject was first introduced to the study, the date 
and, if applicable, time of consent, who participated in the consent discussion, who consented the subject, and any additional person present during the consent process (e.g., 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 102/[ADDRESS_423175] ’s family member[s]), and the information that a copy of the signed ICF was given 
to the subject. 
12.4 Compensation to subjects and investigators 
Idorsia  provides insurance in order to indemnify (with both legal and financial coverage) 
the investigator/site against claims arising from the study, except for claims that arise from 
malpractice and/or negligence.  
The compensation of the subject in the event of study -related injuries will comply with 
applicable regulations. Study subjects will be  reimbursed for the study -related expenses 
(e.g., travel costs, meals, hotel), and may be offered financial compensation for their 
participation in the study only to the extent permitted by [CONTACT_13762] . 
12.5 Protocol adherence/compliance 
The in vestigator must conduct the study in compliance with the IEC/IRB and/or the 
regulatory authority -approved version of the protocol and must not implement any 
deviation/change from the protocol, except when deviation is necessary to eliminate an 
immediate ha zard to the subject. 
If a protocol deviation occurs, the investigator/delegate will inform Idorsia  or its 
representative in a timely manner. The investigator/delegate must document and explain any deviation from the approved protocol. Deviations considered to be a violation of 
ICH-GCP must be reported to the IEC/IRB and regulatory authorities according to Idorsia 
or (overruling) local requirements. 
All protocol deviations will be reported in the CSR. IECs/IRBs will be provided with 
listings of protocol deviations as per local requirements. 
12.[ADDRESS_423176] be submitted to the IEC/IRB and regulatory authorities, according to their requirements.  
12.7 Essential documents and retention of documents 
The investigator/delegate must maintain adequate records necessary for the reconstruction and evaluation of the study. A number of attributes are considered of universal importance to source data and the records that hold those data. These include that the data and records are accurate, legible, contemporaneous, original (or certified copy), attributable, complete, consistent, enduring, and available when needed. 
These records are to be classified into two different categories of documents: ISF and 
subjects ’ source documents. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 103/[ADDRESS_423177] be kept by [CONTACT_1732] 25 years  to comply with Idorsia ’s 
requirements (i.e., as specified in the clinical study agreement), and national and/or 
international regulatio ns, whichever would be the longest period. If the investigator cannot 
guarantee this archiving requirement at the site for any or all of the documents, special arrangements, respecting the data confidentiality, must be made between the investigator and Idorsia to store these documents outside the site, so that they can be retrieved in the 
event  of a regulatory inspection. No study document should be destroyed without prior 
written approval from Idorsia . Should the investigator wish to assign the study records to 
another party, or move them to another location, Idorsia must be notified in advance. 
If the site is using an electronic/computerized system to store subject medical records, it 
can be used for the purpose of the clinical study if it is validated (as  per US [ADDRESS_423178]) and if the CRA has been provided personal and restricted access to study subjects only, to verify consistency between electronic source data and the eCRF 
during monitoring visits.  
If the site is using an electronic/computerized system to store subject medical records but it could not be confirmed that the system is validated or if the CRA could not be provided access to the system, the site is requested to print the complete set of source data needed for verifi cation by [CONTACT_2689]. The printouts must be numbered, stapled together with a 
coversheet, signed and dated by [CONTACT_093]/delegate to confirm that these certified copi[INVESTIGATOR_215182]. The printouts will be considered as the official clinical study records and must be filed either with the subject’s medical records or with the subject’ s eCRF.  
In order to verify that the process the site uses to prepare certified copi[INVESTIGATOR_42874], the CRA  must be able to observe this process and confirm that the comparison of the source 
documents and the certified copy did not reveal inconsistencies. The CRA does not need to verify this process for all data of all subjects but at least for some of them (e. g., first 
subject; regular check during the study of critical data like inclusion/exclusion criteria, endpoints for some subjects) as per Idorsia’ s instructions. If it were not possible for the 
CRA to observe this process, it would not be possible to rely on the site ’s certified copi[INVESTIGATOR_42875].  
12.8 Monitoring 
Prior to study start, a Site Initiation Visit (SIV) will be performed after the required 
essential study documents are approved by [CONTACT_42944]. The stud y treatment will be shipped to 
the site upon approval of the required essential documents. 
The PI [INVESTIGATOR_223138]. Site  Information Tech nology support should also be 
available during the SIV.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 104/[ADDRESS_423179] access to study facilities and all source documents needed to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered in the eCRFs and other protocol -related documents. Idorsia  monitoring standards 
require full verification that informed consent has been provided, verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main efficacy, safety, and tolerability endpoints. Additional checks of the consistency of the source data with the eCRFs will be performed according to the study -specific monitoring 
guidelines. The frequency of the monitor ing visits will be based on subject recruitment rate 
and critical data- collection times.  
The PI [INVESTIGATOR_223139] a subject ’s visit (site visit or telephone 
call), and that all requested subject files (e.g., ICFs, medical notes/c harts, other 
documentation verifying the activities conducted for the study) are available for review by [CONTACT_2689]. The required site personnel must be available during monitoring visits and allow adequate time to meet with the CRA to discuss study -related i ssues.  
The investigator agrees to cooperate with the CRA(s) to ensure that any issues detected in the course of these monitoring visits are resolved. If the subject is hospi[INVESTIGATOR_42878] a hospi[INVESTIGATOR_42869], the investigator is responsible for contact[CONTACT_42948][INVESTIGATOR_215185], in accordance with local regulations. 
A close- out visit will be performed for any initiated site when there are no more active 
subjects and all follow-up issues have been resolved. If a site does not enroll any subjects, 
the close- out visit may be performed prior to study database closure at the discretion of 
Idorsia . 
12.[ADDRESS_423180] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 105/[ADDRESS_423181] be kept by [CONTACT_180535], ICH- GCP, as well as instructions from Idorsia . If the site needs to transfer the 
ISF to another location and/or if site facility can no longer store the ISF, the PI [INVESTIGATOR_341783] . 
If the PI [INVESTIGATOR_341784], or if the site will relocate, the CRA must be notified as soon as 
possible. 
12.10  Audit  
Idorsia ’s Pharmaceutical Development group  representatives  or delegates  may audit the 
investigator site (during the study or after its completion). The purpose of this visit will be 
to determine the investigator ’s adherence to ICH -GCP, the protocol, and applicable 
regulations; adherence to Idorsia ’s requirements (e.g., standard operating procedures ) will 
also be verified. Prior to initiating this audit, the investig ator will be contact[CONTACT_341817] a time for the audit.  
The investigator and site personnel must cooperate with the auditor(s) and allow access to all study documentation (e.g., subject records) and facilities. 
12.11  Inspections 
Health authorities and/or IEC s/IRB s may also conduct an inspection of this study (during 
the study or after its completion) at the site.  
Should an inspection be announced by a health authority and/or IEC/IRB, the investigator must immediately inform Idorsia  (usually via the CRA ) that such a request has been made.  
The investigator and site personnel must cooperate with inspector(s) and allow access to all study documentation (e.g., subject records) and study facilities. 
12.[ADDRESS_423182] the key elements of this protocol and the summary of results on Idorsia ’s 
Clinical Trial Register and within the required timelines on publicly accessible databases 
(e.g., clinicaltrials.gov, EU database), as required by [CONTACT_42951]. 
Study results will be documented in a CSR ( the PAUSe sub -study results will be reported 
in a separate CSR ) that will be signed by [CONTACT_341818]. 
In accordance with the Good Publication Practices and ethical practice, the results of the 
study will be submitted for publication in a peer -reviewed journal. Study results can be 
submitted for presentation at a congress before submission to a peer-reviewed journal. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 106/[ADDRESS_423183] 2017 -004642 -20 
Doc No D- 18.160 
 
 Authorship will be determined in accordance with the Internationa l Committee of Journal 
Editors criteria, and be based on: 
• substantial contributions to the conception or design of the study, or the acquisition, 
analysis, or interpretation of data; and 
• drafting of the publication or critical review for important intellectual content; and  
• providing final approval of the version to be published; and 
• agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. 
The list of authors of any publication of study results may include representatives of Idorsia 
and will be determined by [CONTACT_11402].  
Any study -related publication written independently by [CONTACT_42953] [ADDRESS_423184] alterations 
and/or deletions for the sole purpose of protecting its confidential information and/or pa tent 
rights. Neither the institution nor the investigator should permit publication during such a review period. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 107/[ADDRESS_423185] 2017 -004642 -20 
Doc No D- 18.160 
 
 13 REFERENCES 
[D-15.653] Double -blind, placebo- controlled, randomized, single ascending dose study to 
investigate the tolerability, safety, pharmacokinetics, pharmacodynamics, absolute 
bioavailability, mass balance, and metabolism of ACT -541468 in healthy male 
subjects. Actelion Pharmaceuticals Ltd. Clinical Study Report AC -078- 101. 4 March 
2016. 
[D-16.087] A single -center, open- label, randomized, two-way crossover study to 
investigate the effect of multiple -dose diltiazem on the pharmacokinetics of a single 
dose of [ADDRESS_423186] -541468 in healthy male subjects. Actelion Pharmaceuticals Ltd. 
Clinical Study Report AC -078-103. 28 April 2016.  
[D-16.386] D ouble- blind, placebo- controlled, randomized study to investigate the 
tolerability, safety, pharmacokinetics, and pharmacodynamics of ACT -541468: Part 
A: Multiple -ascending doses in healthy young adults after morning administration; 
Part B: Single -ascending doses in healthy elderly subjects after morning 
administration; Part C: Repeated doses in both healthy young adults and elderly subjects after evening administration. Actelion Pharmaceuticals Ltd. Clinical Study Report AC-078-102. 7 November 2016. 
[D-17.098] A single -center, open- label study to investigate the food effect on the 
pharmacokinetics of ACT -[ADDRESS_423187] -541468 on the pharmacokinetics of midazolam and its metabolite 
1-hydroxy midazolam in healthy male sub jects. Idorsia Pharmaceuticals Ltd. Clinical 
Study Report AC-078-104. 28 November 2017. 
[ACT -541468 IB] Investigator ’s Brochure for ACT -541468 version 5. Idorsia 
Pharmaceuticals Ltd. January 2018. 
[aasmnet.org] American Academy  of Sleep Medicine Standards and Guidelines for the 
Practice of Sleep Medicine, [regularly updated]. Available from:   
http://www.aasmnet.org  
[Ambien
® USPI] Ambien® (zolpi[INVESTIGATOR_6730]) US Package Insert. [LOCATION_002] Food and Drug 
Administration full prescribing information;  
https://www.access data.fda.gov/drugsatfda_docs/label/2017/019908s038lbl.pdf  
[Ancoli- Israel  1999] Ancoli -Israel S, Roth T. Characteristics of insomnia in the United 
States: results of the 1991 National Sleep Foundation Survey. Sleep. 1999;[ADDRESS_423188] 2:S354-58. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 108/[ADDRESS_423189] 2017 -004642 -20 
Doc No D- 18.160 
 
 [APA 2013] Amer ican Psychiatric Association. Diagnostic and statistical manual of 
mental disorders, Fifth Edition. Arlington, VA: American Psychiatric Publishing; 
2013. 
[Balter  1991] Balter MB, Uhlenhuth EHJ. The beneficial and adverse effects of hypnotics. 
J Clin Psychiatry. 1991;[ADDRESS_423190]:16-23.  
[Belsomra® USPI] Belsomra® (suvorexant) US Package Insert. [LOCATION_002] Food and 
Drug Administration full prescribing information; http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s000lbledt.pdf 
[Benca 2004] Benca  RM, Ancoli -Israel S, Moldofsky H. Special considerations in 
insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J Clin Psychiatry. 2004;[ADDRESS_423191] 8:26-35. 
[Bowling 2001] Bowling A, Ebrahim S. Measuring patients ’ preferences  for treatment and 
perceptions of risk. Quality in Health Care. 2001;10(Supplement 1):i2–i8  
[Bretz  2009] Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to 
sequentially rejective multiple test procedures. Stat Med. 2009;28:586-604. 
[Bridges 2011] Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser L.A, Regier DA, 
et al. Conjoint Analysis Applications in Health —a Checklist: A Report of the ISPOR 
Good Research Practices for Conjoint Analysis Task Force, Value in Health 2011;14,403– 413. 
[Buscemi  2007] Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospi[INVESTIGATOR_28947] M, et 
al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta -
analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-50. 
[Buysse  2007] Buysse DJ, Thompson W, Scott J, Franzen PL, Germain A, Hall M, et al. 
Daytime symptoms in primary insomnia: a prospective analysis using ecological momentary assessment. Sleep Med. 2007 Apr;8(3):198–208. 
[Citrome  2014] Citrome L. Suvorexant for insomnia: a systematic review of the efficacy 
and safety profile for this newly approved hypnotic - what is the number needed to 
treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(12):1429-41.  
[Clark 2014] Clark MD, Determann D, Petrou S, Moro D, de Bekker -Grob EW. Discrete 
choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883-902. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 109/[ADDRESS_423192] 2017 -004642 -20 
Doc No D- 18.160 
 
 [Coyle  2001] Coyle D, Wells G, Graham I, et al. The impact of risk on preference values: 
Implications for evaluations of postmenopausal osteoporosis therapy. Value in 
Health. 2001;4(5):385–91.  
[de Lecea 1998] de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. 
The hypocretins: hy pothalamus- specific peptides with neuroexcitatory activity. Proc 
Natl Acad Sci [LOCATION_003]. 1998;95:322–7. 
[Desarnaud  2004] Desarnaud F, Murillo- Rodriguez E, Lin L, Xu M, Gerashchenko D, 
Shiromani SN, et al. The diurnal rhythm of hypocretin in young and old F344 rats. Sleep. 2004;27:851–6. 
[EMA  2011] European Medicines Agency guideline on medicinal products for the 
treatment of insomnia. EMA/CHMP/[ZIP_CODE]/2009 Rev. 1. 7 February 2011. Available from:   
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102351.pdf 
[FDA  1977] Food and Drug Administration (US): Guideline for the clinical evaluation of 
hypnotic drugs. September 1977; Available from:  https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071711.pdf 
[FDA  2007] Food and Drug Administration (US) Requests Label Change for All Sleep 
Disorder Drug Products. Available from:   
https://www.ptcommunity.com/news/20170421/fda- requests -label -change- all-
sleep -disorder- drug-products 
[FDA  2017] Food and Drug Administration (US): Assessment of Abuse Potential of 
Drugs. January 2017; Available from:  https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm198650.pdf 
[Folstein  1975] Folstein MF, Folstein SE, McHugh PR. “Mini- mental state ”: A practical 
method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 
1975;12:189-98 
[Ford  1989] Ford DE, Kamerow DB. Epi[INVESTIGATOR_223141]. An opportunity for prevention? JAMA. 1989;262(11): 1479-84. 
[Fortier -Brochu 2014] Fortier -Brochu E, Morin CM. Cognitive impairment in individuals 
with insomnia: clinical significance and correlates. Sleep. 2014;37(11):1787-98.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 110/[ADDRESS_423193] 2017 -004642 -20 
Doc No D- 18.160 
 
 [Hagan  1999] Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam  TA, Holmes S, et al. 
Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc 
Natl Acad Sci [LOCATION_003]. 1999;96:[ZIP_CODE]–6. 
[Herring  2016] Herring WJ, Connor KM, Ivgy -May N, Snyder E, Liu K, Snavely DB, et 
al. Suvorexant in patient s wit h insomnia: Results from two 3- month randomized 
controlled clinical trials. Biol Psychiatry. 2016;79(2):136-48. 
[Hohagen 1994] Hohagen F, Käppler C, Schramm E, Riemann D, Weyerer S, Berger M. 
Sleep onset insomnia, sleep maintaining insomnia and insomnia wi th early morning 
awakening -temporal stability of subtypes in a longitudinal study on general practice 
attenders. Sleep. 1994;17(6):551-4.  
[Holbrook 2000] Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta -analysis 
of benzodiazepi[INVESTIGATOR_215188]. CMAJ. 2000;162(2):225-33. 
[Johns 1991] Johns MW. A new method for measuring daytime sleepi[INVESTIGATOR_008]: the Epworth 
Sleepi[INVESTIGATOR_7110]. Sleep. 1991;14(6):540-5. 
[Kales  1978] Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical syndrom e. 
Science. 1978;201(4360):1039-41.  
[Kilduff 2000] Kilduff TS, Peyron C. The hypocretin/orexin ligand- receptor system: 
implications for sleep and sleep disorders. Trends Neurosci. 2000;23:359–65. 
[Kuriyama  2014] Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of 
insomnia in adults: a systematic review and meta -analysis. Sleep Med. 
2014;15(4):385-92.  
[Léger  2002] Léger D, Guilleminault C, Bader G, Lévy E, Paillard M. Medical and socio-
professional impact of insomnia. Sleep. 2002;25(6):625-9. 
[Lieberman  2007] Lieberman JA. Update on the safety considerations in the management 
of insomnia with hypnotics: incorporating modified -release formulations into 
primary care. Prim Care Companion J Clin Psychiatry. 2007;9(1):25-31. 
[Lin 1999] Lin L, Faraco  J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder 
canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365-76. 
[Lunesta
® USPI] Lunesta® (eszopi[INVESTIGATOR_11123]) US Package Insert. [LOCATION_002] Food and Drug 
Administration full prescribing information;   
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 111/[ADDRESS_423194] 2017 -004642 -20 
Doc No D- 18.160 
 
 [McCall  2004] McCall WV. Sleep in the elderly: Burden, diagnosis, and treatment. Prim 
Care Companion J Clin Psychiatry. 2004;6(1) :9–20. 
[Mignot 2002] Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et 
al. The role of cerebrospi[INVESTIGATOR_341785]. Arch Neurol. 2002;59(10):1553–62. 
[Morin  1993] Morin CM, Kowatch RA, Barry T, Walton E. Cognitive -behavior therapy 
for late -life insomnia. J Consult Clin Psychol. 1993;61(1):137-46.  
[Neubauer  2014] Neubauer DN. New and emerging pharmacotherapeutic approaches for 
insomnia. Int Rev Psychiatry. 2014;26(2):214-24. 
[NIH  2005] National Institutes of Health, State -of-the- Science Conference Statement on 
Manifestations and Management of Chronic Insomnia in Adults. NIH Consensus and State -of-the-Science Statements. 2005 Jun;13-15;22(2):1-30. 
[Nutt  2006] Nutt D. GABAA receptors: subtypes, regional distribution, and function. J 
Clin Sleep Med. 2006;2(2):Suppl S7-11.  
[Ohayon 2001] Ohayon MM, Zulley J, Guilleminault C, Smirne S, Priest RG. How age 
and daytime activities are related to insomnia in the general population: consequences for older people. J Am Geriatr Soc. 2001;49(4):360–6. 
[Ohayon 2002] Ohayon MM, Smirne S. Prevalence and consequences of insomnia 
disorders in the general population of Italy. Sleep Med. 2002;3(2):115–20. 
[Ohayon 2004] Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. 
Meta- analysis of quantitative sleep parameters from childhood to old age in healthy 
individuals: developi[INVESTIGATOR_215190]. Sleep. 2004;27(7):1255–73. 
[Ohayon 2010] Ohayon MM, Sagales T. Preva lence of insomnia and sleep characteristics 
in the general population of Spain. Sleep Med. 2010;11(10):  
1010–8. 
[Pauker  1981] Pauker SG, McNeil BJ. Impact of patient preferences on the selection of 
therapy. J Chronic Dis. 1981; 34(2–3):77–86 
[Petursson 1981] Petursson H, Lader MH. Benzodiazepi[INVESTIGATOR_215192]. Br J Addict. 
1981;76(2):133-45. 
[Pi[INVESTIGATOR_42849] 2007] Pi[INVESTIGATOR_42882], Crabtree VM, Scherer MR. The future of behavioral sleep 
medicine. J Clin Sleep Med. 2007;3(1):73-9. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 112/[ADDRESS_423195] 2017 -004642 -20 
Doc No D- 18.160 
 
 [Pi[INVESTIGATOR_42849]  2010] Treatment of adult insomnia with cognitive -behavioral therapy. J Clin 
Psychol. 2010;66(11):1148–60. 
[Posner 2007] Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia 
Classification Algorithm of Suicide Assessment (C -CASA): classification of suic idal 
events in the FDA ’s pediatric suicidal risk analysis of antidepressants. Am J 
Psychiatry. 2007 Jul;164(7):1035-43. 
[Rosenthal 1993] Rosenthal L, Roehrs TA, Rosen A, Roth T. Level of sleepi[INVESTIGATOR_223143]. Sleep. 1993;16(3):  
226-32 
[Roth 2007] Roth T. Insomnia: Definition, Prevalence, Etiology, and Consequences. J Clin 
Sleep Med. 2007;[ADDRESS_423196] 5:S7-10. 
[Sakurai  2007] Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and 
wakefulness.  Nat Rev Neurosci. 2007;8:171–81. 
[Samson  2010] Samson WK, Bagley SL, Ferguson AV, White MM. Orexin receptor 
subtype activation and locomotor behaviour in the rat. Acta Physiol (Oxf). 
2010;198:313–24. 
[Scharf  2007] Scharf MB, Black J, Hull S, Landin R, Farber R. Long -term nightly 
treatment with indiplon in adults with primary insomnia: results of a double -blind, 
placebo -controlled, 3-month study. Sleep. 2007;30(6):743-52.  
[Schutte-Rodin 2008] Schutte -Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical  
guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487–504. 
[Sheehan 1996] Sheehan DV, Harnett -Sheehan K, Raj BA. The measurement of disability. 
Int Clin Psychopharmacol 1996;[ADDRESS_423197] 3:S89-95  
[Sheehan  1999] Sheehan D, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M. 
MINI international neuropsychiatric interview. J Clin Psychiatry.  1999:60(18):39-
60. 
[Simon  1997] Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in 
primary care. A m J Psychiatry. 1997;154(10):1417-23. 
[Simpson 2008] Simpson D, Curran MP. Ramelteon: a review of its use in insomnia. 
Drugs. 2008;68(13):1901-19. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 113/[ADDRESS_423198] 2017 -004642 -20 
Doc No D- 18.160 
[Tervonen 2017]
 Tervonen T, Gelhorn H, Sri Bhashyam S, et al. MCDA swing weighting 
and discrete choice experi ments for elicitation of patient benefit- risk preferences: a 
critical assessment. Pharmacoepi[INVESTIGATOR_9697]. 2017;1 –9. 
[Thannickal 2000] Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, 
Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. 
Neuron. 2000;27(3):469–74. 
[Treat  Guidel Med  Lett 2009] Drugs for insomnia. Treat Guidel Med Lett. 2009;7:23-6. 
[Tyrer  1990] Tyrer P, Murphy S, Riley P. The Benzodiazepi[INVESTIGATOR_223144]. J Affect Disord. 1990;19:53-61 
[Zammit 1999] Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of 
life in people with insomnia. Sleep. 1999;[ADDRESS_423199] 2:S379-85. 
[Zeitzer  2003] Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. 
Circadian and homeostatic regu lation of hypocretin in a primate model: implications 
for the consolidation of wakefulness. J Neurosci. 2003;23:3555–60. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 114/[ADDRESS_423200] 3 hours before going to bed. 
A drink is defined as: 
a.A bottle/can of 33 cl / 12 ounces of beer (≈14 grams alcohol)
b.A glass of 10 –12 cl / 4 ounces of wine (≈12 grams alcohol)
c.A small glass of 3 –4 cl / 1 ounce of liquor (≈9 grams alcohol)
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 115/[ADDRESS_423201] 2017 -004642 -20 
Doc No D- 18.160 
Appendix 2 C
affeine content of common beverages  
The content of caffeine in common caffeine beverages is approximately:  
a.A standard cup of brewed or restaurant -style coffee contains approximately
150–[ADDRESS_423202] soda drinks (unless decaffeinated soda drinks) cont ains approximately
50 mg caffeine.
c.A can of energy drink contains approximately 150–[ADDRESS_423203] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 116/[ADDRESS_423204] 2017 -004642 -20 
Doc No D- 18.160 
Appendix 3 F
orbidden and restricted concomitant medications  
1. Forbidden (F) or restricted (R) concomitant medications due to CNS side effects.
To be eligible, subjects must not be treated with CNS- active drugs for 5 half -lives of
the respective drug (but at least 2 weeks) prior to Visit 1. The use of CNS- active
drugs is forbidden or restricted until 24 hours after EOT  (Visit 10).
Drug Class  Examp les Forbidden / 
Restricted  Comment  
Centrally Acting 
Anticholinergics  e.g., tropatepi[INVESTIGATOR_050], oxybutynin,
solifenacin, dimenhydrinate,
dextrometorphan.F 
Antihistamines  Sedating:  e.g., carbinoxamine, 
triprolidine HCl, acrivastine, azatadine, chlorpheniramine,  
doxylamine, hydroxyzine, ketotifen, 
promethazine & timeprazine, 
diphenhydramine HCl.  F 
Non-sedating : e.g., cetirizine, 
desloratidine, fexofenadine, levocabasteine, loratidine.  R 
Non-sedating 
antihistamines may be used 
maximum twice weekly for allergic symptoms.  
Psychotropi[INVESTIGATOR_42884]:  e.g., amphetamine 
derivatives, ephedrine derivatives, 
modafinil, armodafinil, methylphenidate, aripi[INVESTIGATOR_4253], 
pramipexole, levodopa.  F 
Antidepres sants:  e.g., bupropi[INVESTIGATOR_2394], 
citalopram, doxepin, duloxetine, 
escitalopram, fluoxetine, 
fluvoxamine, nefazodone, paroxetine, sertraline, trazodone, 
amitriptyline, clomipramine, 
desipramine, imipramine, mirtazapi[INVESTIGATOR_050], nortriptyline, 
trimipramine, venlafaxine, 
hydracarbazine, moclobemide, 
selegiline.  F 
Antipsychot ics, including depot 
neuroleptics:  e.g., quetiapi[INVESTIGATOR_050], 
olanzapi[INVESTIGATOR_050].  F 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 117/[ADDRESS_423205] 2017 -004642 -20 
Doc No D- 18.160 
Anxiolytics:  e.g., alprazolam, 
buspi[INVESTIGATOR_5331], clorazepate, diazepam, 
flurazepam, lorazepam, midazolam, 
quazepam, temazepam, triazolam.  F 
Hypnotics:  e.g., ramelteon, 
suvorexant, zolpi[INVESTIGATOR_42885].  F 
Cholineste rase inhibitors:  e.g., 
donepezil, galantamine.  
Mood stabiliz ers, e.g., 
carbamazepi[INVESTIGATOR_050], gabapentin, 
lamotrigine, lithium, oxcarbazepi[INVESTIGATOR_050], pregabalin, valproic acid, tiagabine.  F 
Opi[INVESTIGATOR_2438]/Na rcotics : e.g., codeine, 
oxycodone, heroin, marijuana.  R Use of narcotics for pain relief must be avoided if 
there are effective alternative medications 
(such as NSAIDs)  
Centrally  acting muscle relaxants 
with psychotropic effects:  e.g., 
methocar bamol, tetrazepam. R Use of centrally acting 
muscle relaxants must be 
avoided if there are 
effective alternative medications (such as 
NSAIDs)  
Herbal prepar ations with possible 
psychotropic effects : e.g., St John ’s 
Wort, valerian, passiflora, 
hypericum.  F 
Others:  e. g., tryptophan, melatonin.  F 
Anticonvulsants  Barbiturates, benzodiazepi[INVESTIGATOR_1651], 
GABA analogs, hydantoins 
phenyltriazines (e.g., lamotrigine)  
succinimides (e.g., ethosuximide)  F 
Other  Warfarin, heparin, ticlopi[INVESTIGATOR_5325]  F 
Isotrenito in  F 
Systemic  glucocorticoids:  e.g., 
dexamethasone, methylprednisone, 
prednisone.  F Inhaled corticosteroids are 
permitted  
Diet pi[INVESTIGATOR_3353] (pr escription and OTC).  F 
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 118/[ADDRESS_423206] 2017 -004642 -20 
Doc No D- 18.160 
Pseudoephedrine  R May only be used before 
2 pm, and no more than 
twice a week. Dosage is 
limited to 30 mg of active 
ingredient in each tablet. 
Extended release 
formulations are forbidden.  
Anti-emetics:  e.g., domperidone, 
metoclopramide.  F 
GABA = gamma-aminobutyric acid; NSAID = nonsteroidal anti -inflammatory drug; OTC = over -the-counter.  
2.Non-exhaust
ive list of forbidden concomitant medications and diets due to potential
drug interactions with CYP3A4 (moderate and strong inhibitors, inducers).
Those medications must be discontinued no later than within 1 week prior to V isit 2
and are forbidden until 24 hours after EOT  (Visit 10).
CYP3A4 moderate and strong inhibitors and CYP3A4 moderate and strong inducers: 
Inhibitors of CYP3A4  Inducers of CYP3A4  
HIV antivirals: atazanavir, boceprevir, cobicistat, 
darunavir, delaviridine, fosamprenavir , indinavir, 
lopi[INVESTIGATOR_054], nelfinavir, ritonavir, saquinavir, 
telaprevir  HIV antivirals: efavirenz, etravirine  
Antibiotics: ciprofloxacin, clarithromycin, 
erythromycin, norfloxacin, quinupristin, telithromycin, troleandomycin  Antibiotics: nafcillin, rifabutin, rifampin  
Antifungal: fluconazole, itraconazole, 
ketoconazole, posaconazole, voriconazole 
CNS -active: fluvoxamine, nefazodone  CNS -active: carbamazepi[INVESTIGATOR_050], fenobarbital, 
modafinil, phenytoin, St. John’ s Wort  
Cardiovascular: amiodarone, diltiazem, 
dronedarone, verapamil  Cardiovascular: bosentan  
Aprepi[INVESTIGATOR_053], conivaptan, cimetidine, imatinib  
Grapefruit and grapefruit juice  
Seville oranges (bitter) and Seville oranges juice  
CNS = central nervous system; CYP  = cytochrome P450; HIV = human immunodeficiency virus.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 119/[ADDRESS_423207] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 121/[ADDRESS_423208] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 122/[ADDRESS_423209] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 123/[ADDRESS_423210] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 124/[ADDRESS_423211] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 125/[ADDRESS_423212] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 126/[ADDRESS_423213] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 127/[ADDRESS_423214] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 128/[ADDRESS_423215] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 129/[ADDRESS_423216] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 130/[ADDRESS_423217] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 131/[ADDRESS_423218] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 133/[ADDRESS_423219] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 134/[ADDRESS_423220] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 135/[ADDRESS_423221] -541468  
Insomnia disorder  
Protocol ID-078A301  
Version 4  
30 July  2018, page 136/[ADDRESS_423222] -541468  
Insomnia disorder  
Protocol ID-078A301  
Version 4  
30 July  2018, page 137/[ADDRESS_423223] -541468  
Insomnia disorder  
Protocol ID-078A301  
Version 4  
30 July  2018, page 138/[ADDRESS_423224] -541468  
Insomnia disorder  
Protocol ID-078A301  
Version 4  
30 July  2018, page 139/[ADDRESS_423225] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 140/[ADDRESS_423226] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 141/[ADDRESS_423227] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 142/[ADDRESS_423228] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 143/[ADDRESS_423229] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 144/[ADDRESS_423230] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 145/[ADDRESS_423231] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 146/[ADDRESS_423232] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 147/[ADDRESS_423233] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 148/[ADDRESS_423234] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 149/[ADDRESS_423235] -541468  
Insomnia disorder  
Protocol ID -078A301 
Version  4 
30 July  2018, page 150/[ADDRESS_423236] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 151/[ADDRESS_423237] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 152/[ADDRESS_423238] -541468  
Insomnia disorder  
Protocol ID -078A301  
Version 4  
30 July  2018, page 153/[ADDRESS_423239] 2017 -004642 -20 
Doc No D- 18.160 
